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Introduction 
 
1 Myrtus communis and myrtucommulone 
 
Myrtus communis L., also called `True Myrtle´, belongs to the family of the 
Myrtaceae (Rosopsida, Rosidae, Myrtales, Myrtaceae, Myrtus).   
To this family also the eucalypt 
tree, guava and allspice (myrtle 
pepper) are assigned. The myrtle 
is an evergreen bush which 
grows mainly in mediterranean 
areas such as Sardinia and 
Corsica. The plant has small 
lanceolate leaves and delicate 
white, flavoursome flowers 
which develop into darkly 
coloured berries.     Fig. Myrtle (Myrtus communis) 
Aside from its use in mediterranean cuisine (as substitute for pepper and bay 
leaves, to make liqueur), myrtle was described by the greek erudite Pedanios 
Dioskurides in his `materia medica´ as treatment of minor burns, eschar, 
inflammation of the skin or the eyes, ulcer and excess flow of sweat.  
The dried leaves contain up to 0.5% oily components with 23% limonene, 20% 
linalool, 51.3% α-pinene, 34.7% 1,8-cineole, myrtenol, myrtenol acetate, 0.12% 
myrtucommulone A (MC) and others [1, 2]. 
There are only a few publications concerning the effect of myrtle extracts, most of 
them stating MC to have analgesic [3], antibacterial [4, 5], antihyperglycaemic [6-
8], antioxidant [9] and antigenotoxic [10] properties.  
In his review about aspirin and analgesic treatments, Levesque reports that 
Assyrians and Egypts used a preparation of myrtle leaves for the alleviation of 
joint pains [3], another example for the use of myrtle in traditional medicine.  
More scientifically funded are studies of Al-Saimary et al.. They tested aqueous 
extracts of myrtle leaves on inhibition of bacterial growth in Pseudomonas 
aeruginosa and Staphylococcus aureus, the predominant pathogens found in burn 
 Introduction 21 
 
infections. Interestingly, the effects of myrtle extracts on diameter of growth 
inhibition zones by agar diffusion method lay within the limits of some antibiotics 
(penicillin, tetracyclin, gentamycin and others) which were tested alongside (5-20 
mg/ml) [4]. 
Bonjar et al. were also trying to give the use of folkloric medicine a scientifically 
funded background. They were screening the antibacterial activity of methanolic 
plant extracts (Myrtus communis seeds as one of them) on gram-negative and 
gram-positive bacteria in general and found that these myrtle extracts are highly 
active (minimal inhibitory concentration of 0.62 mg/ml) against Staphylococcus 
aureus (inflammation of the skin and lung), Bacillus cereus (intoxication of 
aliments) and Bacillus bronchiseptica (infection of the respiratory system) [5]. 
Aside from these antibacterial effects of myrtle extracts, it could be shown by 
Onal et al. that one fraction of myrtle extracts could inhibit α-glucosidase activity 
in vitro with an IC50 of 38 µg/ml. Alpha glucosidase inhibitors are well 
established as treatment in patients with type II diabetes [8]. And act by delaying 
the absorbance of carbohydrates in the intestine. Furthermore, this possible 
therapeutic benefit was supported by in vivo studies of myrtle oil in alloxan-
diabetic rabbits by Sepici et al. [7]. Again, the incitement for this investigation 
came from (this time Turkish) folk medicine. Here, leaves from Myrtus communis 
and the volatile oil of the leaves are both used to lower blood glucose levels in 
type 2 diabetic patients. Sepici et al. could show that myrtle oil (administered in 
50 and 100 mg/kg per day) significantly lowered blood glucose by 51% in 
alloxan-diabetic rabbits but not in normoglycaemic animals without affecting 
insulin levels in the blood. The authors postulated that inhibition of the α-
glucosidase in the small intestinal mucosa, induction of glukokinase and higher 
rates of glycogenesis are the reasons for the reduction in blood glucose levels [7].  
Hayder et al. used myrtle extracts obtained by different extraction methods and 
screened their ability to block Aflatoxin B1- (AFB1) and Nifuroxazide-induced 
SOS response in Escherichia coli PQ37. The SOS response in bacteria is a DNA 
repair system thought responsible for the evolvement of antibiotic resistance. The 
methanol and aqueous myrtle extracts showed the highest inhibition of SOS 
response induced by AFB1. Aside from these antigenotoxic effects, some of the 
myrtle extracts showed free-radical scavenging activity against the DPPH (1,1-
diphenyl-2-picrylhydrazyl radical [10].  
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The antioxidant effect by myrtle extracts was also investigated by Romani and 
coworkers. Inspired by the anti-inflammatory uses of myrtle in folk medicine they 
prepared liquid-liquid extracts of myrtle leaves with different solvents. 
Hydroalcoholic extracts, ethylacetate and aqueous extracts had the highest 
antioxidant activities (0.36 µM, 2.27 µM and 2.88 µM respectively) in copper ion 
induced oxidation of human low density lipoprotein (LDL), apparently due to the 
presence of galloyl derivatives [9]. 
All this research so far could only hint to the part or the parts of myrtle extract 
which are responsible for the effects observed. 
OH
O
OOH
O
OHO
O
OH OH
 
Fig. myrtucommulone A (MC) 
 
In 1974, a non-prenylated acylphloroglucinol named myrtucommulone A (MC) 
(see Fig.) and its antimicrobial properties against gram-positive bacteria (S. 
aureus, B. subtilis, Streptococcus faecalis and others) was described for the first 
time by Rotstein et al. [11]. His aim was to isolate active compounds from 
antibacterial plant extracts and test them in growth inhibition zone tests for the 
ability to affect bacterial growth. Bacteria were seeded on agar plates, the tested 
compounds were administered to a paper disk and this in turn applied to the agar 
plates. 80 µg MC per disk had the same effect on growth of the gram-positive 
bacteria tested as 10 U penicillin or streptomycin per disk. Rotsteins work is 
concluded by the remark that `phenolic compounds are more active against gram-
positive than gram-negative bacteria´ and that `the presence of organic matter 
such as milk or serum effectively reduces their activity´. In vivo infections in mice 
induced by intraperitoneal injection of S. aureus were not affected by application 
of MC as a paste [11]. Another model (acute inflammation) was tested by Rossi 
and coworkers who could show just recently that MC, when injected 
intraperitoneally, could significantly reduce paw oedema and pleurisy induced by 
carrageenan [12]. Paw oedema were reduced dose-dependently (0.5, 1.5 and 4.5 
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mg/kg i.p.) by MC. For the effect of MC in the model of pleurisy the authors 
show that 4 h after carrageenan injection in the pleurisy model, MC reduced: 1) 
the exudate volume and leukocyte numbers; 2) lung injury (histological analysis) 
and neutrophil infiltration (myeloperoxidase activity); 3) the lung intercellular 
adhesion molecule-1 and P-selectin immunohistochemical localization; 4) the 
cytokine levels (tumor necrosis factor-α and interleukin-1 β) in the pleural exudate 
and their immunohistochemical localization in the lung; 5) the leukotriene B4, but 
not prostaglandin E2, levels in the pleural exudates; and 6) lung peroxidation 
(thiobarbituric acid-reactant substance) and nitrotyrosine and poly (ADP-ribose) 
immunostaining.  
 
Appendino et al. published in 2002 [1] the testing of MC on antibacterial 
properties in multidrug resistant Staphylococcus aureus strains (MDR). They 
showed that MC could inhibit growth in strains with efflux mechanisms of 
resistance for macrolides, tetracyclines and fluoroquinolones (minimal inhibitory 
concentration (MIC)
 
= 0.5 - 2 µg/ml). For comparison: in the strains of 
tetracycline and fluoroquinolone resistance, the antibiotic tetracycline had a MIC 
of 256 µg/ml and 32 µg/ml respectively. 
 
Furthermore, it was published that MC has antioxidative properties [13] and might 
be (at least partly) responsible for the antioxidative effect of myrtle extracts as 
described by Romani [9]. It was observed that MC could protect linoleic acid in 
vitro against auto-oxidation and oxidation mediated by FeCl3 and EDTA.  
The effect of myrtle extracts on LDL oxidation could be confirmed with isolated 
MC by Rosa et al. [14]. MC and the truncated form of MC, semi-
myrtucommulone (S-MC), showed strong antioxidant activity in vitro towards 
thermal, solvent-free degradation of cholesterol. Pre-treatment with MC could 
preserve LDL from oxidative damage induced by copper ions and could also 
protect polyunsaturated fatty acids and cholesterol from oxidation. This might be 
an important effect of MC when used as treatment in cardiovascular diseases. 
 
Many data were obtained about the anti-inflammatory properties of hyperforin 
from St Johns worth (Hypericum perforatum), a prenylated acylphloroglucinol 
and a structure analogue of MC [15-17]. In regard to the anti-inflammatory effect 
24 Introduction 
of MC and its molecular targets, it has been shown that MC can directly inhibit 
cyclooxygenase-1 (COX-1) in platelet homogenates and intact platelets (IC50 = 17 
µM) and can inhibit 5-lipoxygenase (5-LO) in granulocytes (PMNL) (IC50 = 1.8 
µM) after stimulation with arachidonic acid and ionomycin. This inhibition of 5-
LO was not competitive. Furthermore, the signaling of G protein coupled 
receptors (GPCRs) activated by fMLP leading to the release of Ca2+ from 
intracellular stores, to the formation of reactive oxygen species (ROS) and to 
elastase release from granules was prevented by MC (IC50 = 0.55 µM, IC50 = 0.9 
µM and IC50 = 0.24 µM). However, the release of Ca2+ and elastase and the 
formation of ROS induced by ionomycin were not or only partly affected (ROS 
production with 25% rest activity) probably by circumventing GPCR signaling 
using ionomycin. In the light of these effects, MC was suggested as potent anti-
inflammatory agent with possible therapeutic benefit in treatment of inflammation 
related diseases [18].  
The findings of the work done by Dr. C. Feißt et al. will be further explored in this 
thesis, trying to give a new perspective of the effect of MC on GPCR signaling 
concerning apoptosis and cancer. 
Concerning GPCRs, another work was published by Carroll et al. [19] showing 
that MC A and structural homologues of MC isolated from the seeds of Corymbia 
scabrida, possess significant competitive affinity to the thyrotropin-releasing 
hormone receptor-2 (TRHR2) in rat HEK2935 cells with an IC50 value of 39 µM 
for the tested TRH. Carroll et al. also observed an interesting property of MC A 
by 1H-NMR. The phenolic protons and the adjacent carbonyl oxygens of the 
molecule obviously form strong hydrogen bonds which prevent the forming of 
hydrogen bonds with the solvents used, making the compound non-polar. 
Furthermore, on treatment with acid, MC A underwent cyclisation and 
dehydration giving a symmetrical pentacyclic compound. 
Koeberle et al. could prove in a cell free assay that MC inhibits isolated 
microsomal prostaglandin E2 synthase-1 (mPGES-1) with an IC50 of 1 µM in a 
reversible fashion. MC could inhibit PGE2 formation in whole A549 cells (human 
lung carcinoma epithelial cells) and in human whole blood in low micromolar 
concentrations (IC50 = 30 µM and IC50 > 30 µM respectively). Interestingly, no 
effect on cyclooxygenase 2 (COX-2) up to 30 µM MC in either A549 cells or on 
the isolated enzyme could be detected. Cellular and cell-free COX-1 was inhibited 
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by MC as shown before [18] with an IC50 > 15 µM. This higher inhibitory 
specifity of MC towards PGE2 synthesis by mPGES-1 gives many perspectives in 
treating inflammation and fever, since common treatment often targets the entire 
prostaglandin biosynthesis by inhibition of COX-1 and COX-2 (aspirin, 
diclofenac, ibuprofen, celecoxib) leading to side effects like gastrointestinal 
ulceration and/or heart attacks [20]. 
 
All research on MC done so far attempted to explain the effects of myrtle extracts 
in traditional medicine on inflammation, diabetes and bacterial infections as well 
as investigating the role of the myrtle constituent MC A in this respect. 
Indeed, it was suggested that MC might be responsible for almost all effects  of 
myrtle extracts observed so far. However, plant extracts might have effects related 
to the content of different active substances and sometimes the concerted action of 
multiple compounds could be responsible for the observed `outcome´. 
 
Recently, more and more attention has been focussed on mechanisms leading 
from inflammation to development of cancer.  
During studies concerning the regulation of the 5-lipoxygenase [21], another 
enzyme important in inflammation, it was found that acylphloroglucinols and 
especially MC could induce apoptosis in cancer cell lines [22]. According to these 
findings, the aim of the present investigation was to elucidate the exact 
mechanism of the pro-apoptotic effect of MC on apoptosis and also to find a 
possible connection between the effects on signal transduction [18] and apoptosis 
induction.  
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2 Cancer 
During the last decades, cancer is gaining more and more in importance especially 
in developed countries. According to the WHO, cancer causes 13% of all human 
deaths (2006). 
The term cancer refers to a group of diseases affecting all parts of the body. It 
develops from one single abnormal cell which shows uncontrolled growth, 
invasiveness and in some cases metastasising properties. The reasons for the 
development of this disease are manifold but apart from the patient’s genetic 
disposition, many external substances called carcinogens are initiators of this cell 
degeneration. Among carcinogens, radiation (UV and ionising), tobacco smoke, 
aflatoxin and infections by certain viruses (e.g. hepatitis B, human papilloma 
Virus, HIV) are well recognised. 
The most diffuse types of cancer are lung, stomach, colorectal, liver and 
breast/prostate cancer. By taking care of a healthy lifestyle and decreasing the 
exposition to risk factors, about 30% of all cancers could be prevented. 
Cancers are named after the first degenerated cell they are derived from. 
Carcinomas are cancers of epithelial origin (breast, lung, prostate and colon 
cancer), sarcomas are tumors derived from connective tissues, lymphomas and 
leukemias from hematopoietic cells and blastomas are tumors of 
immature/embryonic tissue. 
2.1 Leukaemia 
Leukaemia is the cancer derived from and found in the blood and bone marrow, 
manifesting itself in abnormal proliferation of white blood cells (leukocytes). The 
first classification into subtypes gives the classes of acute and chronic leukemia. 
The acute form consists of the rapid uncontrolled proliferation of immature blood 
cells which determines a reduced ability of the bone marrow to give healthy 
mature blood cells. If not treated directly, the abnormal cells enter the blood 
circulation and spread themselves over the whole body. This type of leukaemia is 
mostly found in children. The chronic form of leukaemia includes the excessive 
but slow proliferation of mature blood cells which progresses over years. This 
form is mainly found in elder people.  
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A different classification takes into consideration which kinds of cells are 
affected. In the lymphoblastic forms the progenitors of lymphocytes are affected 
and in the myeloid form the type of marrow cell developing into red blood cells or 
erythrocytes. Therefore one can distinguish four different types of leukemia: acute 
lymphoblastic leukaemia (ALL), chronic lymphoblastic leukaemia (CLL), acute 
myeloid leukaemia (AML), and chronic myeloid leukaemia (CML).  
The causes for developing leukemia are diverse. As in other types of cancer, 
cancerogenes like radiation, virus infections (human T-lymphotropic virus), 
chemicals like benzene and hair dyes as well as the use of tobacco can be a 
reason.  
Treatment of leukemia involves the use of interferons, chemotherapeutics (often 
in combination therapy as to avoid disease resistance), radiation therapy and bone 
marrow transplant. Interferon α (IFNα) is a (glyko-) protein released by 
leukocytes, monocytes and fibroblasts upon infection of a cell by a virus. When 
IFNα binds to its specific receptor on the surface of the infected cell, it activates 
Jak/Stat kinases which bind to the interferon stimulated response element (ISRE) 
leading to activation of specific genes. This helps to reduce the abnormal cell 
proliferation and makes degenerated cells more susceptible for the removal by the 
immune system. This property is used as treatment in newly diagnosed patients 
who are not candidates for bone marrow transplants. The most common treatment 
in AML is the combination of three days intravenous administration of DNA 
intercalating anthracyclines (doxorubicin, daunorubicin) and seven days treatment 
with the bone marrow suppressor Arabinosyl-Cytosin. As third chemotherapeutic, 
6-thioguanine can be added which is incorporated into RNA and DNA and leads 
subsequently to cell cycle arrest and apoptosis. Tretinoin (Vesanoid®), the all -
trans retinoic acid (ATRA) (the acid form of vitamin A) is another possibility to 
treat AML. It is given orally and causes immature blood cells to differentiate and 
eventually die.  
All these treatments cause severe side effects ranging from cardiac damage, 
gastrointestinal damage, nausea, vomiting, fatigue, bleeding, fever, chills to 
hyperleukocytosis, weight gain, edema and pleural effusion (ATRA syndrome). 
The five year relative survival rate has quadrupled during the last 50 years and is 
for AML 21.3% in total and 55.2% for children under 15 years [Leukemia & 
Lymphoma society]. 
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Of course, research is advancing to either circumvent possible disease resistance 
to common drugs [23, 24], but also to find new drugs and therapies with improved 
mode of action and less side effects [25-27]. In the present investigations, data 
supporting the use of MC as an excellent candidate to treat leukaemia will be 
provided.  
2.2 Cancer and inflammation 
It has been observed that chronic inflammation caused by e.g. Heliobacter pylori 
(ulcer), by the immune disorder ulcerative colitis or by the Hepatitis B virus, 
dramatically increases the risk of developing stomach, colon or liver cancer. On 
the other hand, patients who regularly take medication such as non-steroidal anti-
inflammatory drugs (NSAIDs) have a lower risk of developing cancer [28]. 
Research focussed on finding a reason for the connection of chronic inflammation 
and cancer, and two possible ways are thought to be critical: the activity of 
transcription factor nuclear factor kappa-light chain enhancer of activated B-cells 
(NFκB) [29] and the action of inflammatory active immune cells [30].  
Immune cells are attracted to infected cells by cytokines and other 
chemoattractants. When reaching the infected or degenerated cell they release 
reactive oxygen species (ROS), cytokines and growth factors in order to further 
stimulate immune responses and to eliminate pathogens and the infected cell. 
However, these released factors seem to rather stimulate tumour growth and, even 
worse, stimulate tumour migration.  
NFκB is overactive in some cancer types, has antiapoptotic properties [29] and 
functions as a tumour promotor in inflammation-associated cancer [31]. Upon 
stimulation with growth factors, cytokines (TNFα, ILβ), bacterial (e.g. 
lipopolysaccharide (LPS)) or viral antigens NFκB is activated and can regulate the 
expression of the COX-2 gene which encodes an enzyme needed for the 
production of proinflammatory, tumour-inducing prostaglandin E2 (PGE2) [32] 
and which can induce blood vessel growth towards tumour cells [33, 34]. Thus, 
cytokines and growth factors released by immune cells together with activation of 
NFκB in cancer cells may act concertedly to promote inflammation, tumour 
growth and migration and to inhibit apoptosis. 
Another theory on this topic has been recently developed. It was observed that the 
amount of myeloid derived suppressor cells (MDSC) was significantly increased 
 Introduction 29 
 
in tumour tissue, spleen and peripheral blood of tumour bearing mice or cancer 
patients [35, 36] and that T-cell activity in these patients was impaired. MDSC are 
thought to be immature myeloid cells but recently it was found that they have a 
phenotype similar to granulocytes [37]. They normally suppress antibody 
producing B-cells, T-helper cells (CD4+) and T-killer cells (CD8+). Their task is 
to control inflammation and prevent an overactivation of immune responses. 
MDSCs prevent for instance binding of the antigen to the T-cell receptors [36] by 
the involvement of ROS and peroxynitrite. The vascular endothelial growth factor 
(VEGF) released by tumour cells can trigger accumulation of MDSC in tumour 
tissues and MSDCs in turn release VEGF thus further stimulating tumour growth 
[38]. Also IL1β and the overexpression or constitutive expression of COX-2, 
leading to elevated amounts of PGE2, are thought to induce the accumulation and 
activation of MDSCs [39-41] since MDSCs express the PGE2 receptor E-
prostanoid 2 (EP2). Obviously, MDSCs/granulocytes also influence the amounts 
of the T-cell activator L-arginine by release of arginase 1 [42] probably from 
granules [37]. Arginase hydrolyses L-arginine to ornithine and urea. By this 
depletion of arginine, T-cell proliferation and cytokine production is inhibited and 
the expression of the T-cell receptor CD3-zeta chain is reduced [43, 44].  
The important immunosuppressant task of MDSCs in acute inflammation 
becomes threatening when, during chronic inflammation or cancer, the offending 
agent is not removed. Then the inactivation of T-cells by MSDCs/granulocytes 
leads to further tumour growth and facilitates tumour migration. The beneficial 
effect of therapeutics like COX- and mPGES-inhibitors or anti-inflammatory 
drugs in general (Celecoxib, aspirin, indomethacin) as well as agents that interfere 
with arginase activity (Viagra, Cialis) on progression and invasiveness of tumours 
is well established by now. MC, as anti-inflammatory [12] and, as this study will 
prove, anti-cancer compound [45], is well worth being (and already was) tested in 
this respect [46]. 
 
2.3 Metabolism of cancer cells 
Over 80 years ago, Warburg published his idea about altered metabolism in 
cancer cells which is hence known as the Warburg effect. He examined healthy 
and cancerogenous cells from the human liver and observed elevated glucose 
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uptake and an increased rate of glycolysis in cancer cells compared to non-
transformed cells [47]. He postulated that the effect he saw was due to changes or 
to damage of mitochondrial oxidative phosphorylation rendering glycolysis the 
only source for ATP synthesis. Furthermore, he observed a connection between 
glycolitic ATP production and aggressiveness of cancer cells [48]. He suggested 
that the impaired function of mitochondria is even the cause for cancer 
development and that cancer cells might be eliminated by inhibition of oxidative 
phosphorylation. This would decrease mitochondrial function below a critical 
point important for cell survival, whereas normal cells could still compensate this 
loss of mitochondrial function. Cancer cells obviously have still functioning 
oxidative phosphorylation and do produce ATP by ATPase activity (although only 
decreased levels) [49]. 
More recent work on this topic showed that tumor hypoxia and the hypoxia 
inducible factor (HIF) led to altered glucose metabolism. Due to high amounts of 
energy needed and the local vasculature being unable to supply enough oxygen to 
the cancer cell, cells become hypoxic and change their main source of energy 
production from mitochondrial respiration to glycolysis activated by HIF. HIF 
itself influences the activity and the expression of enzymes such as pyruvate 
dehydrogenase [50, 51], lactate dehydrogenase and others [52]. Additionally, it 
inhibits mitochondrial biogenesis and respiration by repression of c-Myc activity. 
The transcription factor c-Myc leads also to altered gene expression and activity 
of metabolic enzymes [53].  
Aside from HIF, the loss of p53, overactivation of protein kinase B (PKB/Akt), 
overexpression of lactate dehydrogenase (LDH) genes and altered lipid 
metabolism are thought to be the main changes in metabolism of cancer cells or 
are changes which might even lead to the development of cancerogenous 
properties in a cell. 
PKB/Akt is a serine threonine kinase playing a pivotal role in survival, 
proliferation and metabolism [54, 55]. Its activation is triggered by insulin and 
various growth factors and involves phosphatidylinositol-3-dependent kinase 
(PI3K). It induces aerobic glycolysis [56], is responsible for glucose transporter 
(GLUT) translocation to the plasma membrane [57] and stimulates mitochondria-
associated hexokinase (HK) activity [58]. HK-1 and -2 are located on 
mitochondrial membranes, are part of the permeability transition pore and, when 
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active, suppress apoptosis and maintain the mitochondrial membrane potential 
(∆Ψm, see section below).  
P53 is the major tumor suppressor in the cell and is mutated in many cancer types. 
It protects the genome by detecting DNA-damage, inducing cell cycle arrest and 
triggers DNA-repair or, if damage is irreparable, induces apoptosis. In non-
transformed cells p53 is activated by an elevated AMP/ATP ratio and functions as 
metabolic checkpoint [59]. Elevated AMP/ATP levels indicate energy depletion 
and eventually lead to cell cycle arrest. Energy depletion can also lead to the 
activation of the AMP activated protein kinase (AMPK) which induces catabolic 
pathways which includes increased glucose uptake, fatty acid oxidation and 
stimulation of mitochondrial metabolism [60]. Tp53 induced glycolysis and 
apoptosis regulator (TIGAR) is activated by p53 and might regulate production of 
ROS [61]. It leads to decreased levels of fructose-2,6-bisphosphate, a positive 
regulator of glycolysis, thus shifting the flux of the early substrate of glycolysis 
glucose-6-phosphate towards the pentose phosphate pathway (PPP). Due to 
increased NADPH concentrations by the increased activity of the PPP, the amount 
of reduced glutathione (GSH) rises and is able to scavenge reactive oxygen 
species (ROS). In many cancer types, p53 is mutated or deleted (see section 
HL60) resulting in decreased TIGER expression, which stimulates glycolysis and 
ROS production, leads to low levels of NADPH and subsequently leads to 
activation of PKB/Akt [62]. In p53 -deficient cells, the p53-dependent expression 
of the cytochrome oxidase 2 (SCO2) is lost and therefore impairs mitochondrial 
respiration [63].  
The lactate dehydrogenase catalyses the conversion of pyruvate to lactate under 
hypoxic conditions. Hypoxia averts metabolisation of pyruvate in the citric acid 
cycle since oxygen is needed for mitochondrial endoxidation. LDH expression is 
induced by c-Myc activity and helps cancer cells to survive under hypoxic 
conditions [64].  
In many cancer cell types, the lipid metabolism is shifted towards high rates of de 
novo fatty acid synthesis probably to support the increased need for membrane 
biosynthesis in highly proliferating cancer cells. This aim is achieved by 
overexpression of the fatty acid synthesis (FASN) [65-67]. 
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All metabolic changes observed so far occur to support the energy needs of the 
highly proliferating cancer cell and rendering glycolysis as only source of ATP 
production. 
 
 
Fig. Metabolism of cancer cells [68] (description see text). GLUT = glucose transporter, lac = 
lactate, pyr = pyruvate, LDH = lactate dehydrogenase, PK = pyruvate kinase, PGM = 
phosphoglucomutase, HIF = hypoxia inducible factor, HK = hexokinase, FASN = fatty acid 
synthase, AcCoA = Acetyl-Coenzyme A, βOx = beta oxidation, SCO2 = cytochrome oxidase 2, FA 
= fatty acid. 
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3 Apoptosis  
Apoptosis is a term derived from the greek απόπτόσισ (`apo´ = from and `ptosis´ 
= fall) [69], referring to the falling of petals from a flower, since one event of 
apoptosis is the formation of apoptotic bodies making the cell look like a flower 
losing its petals. Apoptosis is the so-called programmed cell death, a mechanism 
to control cell proliferation or triggered in response to irreparable (DNA-) damage 
to the cell. It takes part in fetal development [70] as well as for example in 
elimination of self-reactive lymphocytes and downregulation of lymphocytes after 
immune response [71, 72]. Non functional apoptosis results in neurodegenerative 
diseases (Parkinson´s, Alzheimer´s) and hypothropy (when it is exaggerated) or in 
cancer (when it results insufficient). In contrast to necrosis which is always 
involving physical damage to the cell and leads to the release of cell debris into 
the surrounding matrix, causing an inflammatory response, apoptosis is the well 
organised `clean´ death of a cell.  
Caspases are cysteine proteases that cleave after aspartate and are responsible for 
the morphological changes recognised as apoptosis [73]. The morphological 
changes include: losing of cell-cell contact, inhibition of translation, condensation 
of cells and organelles, condensation of chromatin, DNA fragmentation, 
fragmentation of the nucleus, loss of asymmetry of membrane lipid composition, 
constriction of small membrane enclosed cell fragments known as apoptotic 
bodies which then are eliminated by phagocytosis. These events finally result in 
necrosis when phagocytotic cells are not able to cope with high rates of apoptosis 
or in the case of total absence of phagocytotic cells (in cell culture) [74]. 
However, under normal conditions, apoptosis occurs without leakage of cell 
contents and without inflammatory response. Apoptosis is about 20 times faster 
than mitosis and it is therefore almost impossible to detect apoptotic cells in vivo. 
The signals leading to apoptosis can be manifold: starvation, damage beyond 
repair from radiation or toxic chemicals, infection by a virus etc. Then the cell 
itself decides to undergo apoptosis or this decision is made by a cell of the 
immune system. Therefore one differentiates between two ways of apoptosis 
induction. 
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3.1 Pathways of apoptosis induction 
There are two main ways of apoptosis induction: the extrinsic way and the 
intrinsic way. The extrinsic way of apoptosis induction involves the activation of 
a death receptor (DR). They are tumor necrosis factor receptors (TNF R) or tumor 
necrosis factor-related apoptosis-inducing ligand receptors (TRAIL). Fas is the 
best known of these receptors concerning apoptosis [75]. It is also referred to as 
CD95 or Apo-1. Upon binding of the Fas ligand, which is for example expressed 
on an activated T-cell, the receptor trimerises and forms the death inducing 
signaling complex (DISC) with the Fas associated death domain (FADD) [76] and 
caspase 8 or 10 involving hexa-α-helical death domains (DD) and death effector 
domains (DED). This formation of DISC is necessary for cleavage of the 
zymogen procaspase 8 to the active form [77]. The initiator caspase 8 then 
activates the effector downstream caspase 3 in a proteolytic cascade. On the other 
hand the intrinsic way involves cytochrome c release from mitochondria induced 
by various stimuli such as oxidative stress and treatment with cytotoxic drugs. Not 
only cytochrome c is released but also a great variety of other proteins such as 
AIF (apoptosis inducing factor) [78] and EndoG (endonuclease G), both DNases 
and Smac/Diablo (second mitochondria derived activator of caspases), eliminating 
the inhibitory effect of IAPs (see section caspases) [79]. The exact mechanism or 
the initial reason for protein release from mitochondria is still elusive and 
probably involves loss of mitochondrial membrane potential (∆Ψm), the 
permeability transition pore and pore formation by Bcl-2 proteins (see section 
below). Cytochrome c binds to the apoptotic protease-activating factor 1 (Apaf1). 
This triggers the formation of the apoptosome consisting of seven cytochrome c, 
seven dATP and seven procaspase 9 molecules [80, 81]. Upon apoptosome 
formation caspase 9 becomes active and can then in turn activate caspase 3. 
3.2 Caspases 
As mentioned above, caspases are cysteine aspartyl specific proteases responsible 
for the biochemical changes within the cell observed during apoptosis. In humans, 
14 caspases have been identified so far [82] being grouped according to their 
amino acid sequence or their protease specificities. On the base of their function, 
they are often referred to as initiator caspases, standing far upstream the signaling 
cascade, or effector caspases being downstream close to the substrate targets [73].  
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The targets of effector caspases include protein kinases and other signal 
transducing proteins, proteins of the matrix and the cytoskeleton, chromatin 
modifying proteins or DNA repair proteins (poly ADP-ribose polymerase, PARP) 
and inhibitory subunits of endonucleases (inhibitor of caspase activated DNase, 
ICAD)[73, 83].  
From a structural point of view, initiator caspases have a large N-terminal 
prodomain containing either death effector domains (DED) (e.g. caspase 8 and 
10) , or caspase recruitment domains (CARD) (caspase 2 and 9). Effector caspases 
(e.g., caspase 3, 6 and 7) have a significant shorter N-residue and they depend on 
activation by initiator caspases. During activation, the zymogen is cleaved to a 
small (10 kDa) and a larger (20 kDa) fragment and usually forms a heterotetramer 
from two small and two big subunits to become active [83]. In the case of caspase 
8, the weak protease activity of the uncleaved zymogen (around 1% of the fully 
active form) leads to trans-processing of two caspase 8 molecules when brought 
together (induced proximity model) [84]. 
This simple model of caspase activation and apoptosis induction is far from 
complete. For example, it has been recently shown that caspase 3 and 7 are not 
only effector caspases, but they are able to act early in apoptosis inducing 
mitochondrial events like cytochrome c release [85]. Other findings state that 
caspase 8 can be activated by caspase 9 or 3 implying the function of an 
amplification loop [86, 87].  
 
The family of IAP (inhibitor of apoptosis) proteins are a family of apoptosis 
repressors [88, 89]. Most of them have been shown to bind and inactivate 
caspases, mainly the initiator caspase 9 and the effector caspases 3 and 7 [90-92] 
although they also have a role in controlling protein turnover [93]. 
 
3.3 Bcl-2 proteins 
The mitochondrial way of apoptosis induction is mainly regulated by the 
concerted action of pro- and anti-apoptotic Bcl-2 proteins. This is a class of 
proteins mostly found associated to mitochondria. Bcl-2 (from B-cell lymphoma) 
was the first oncogene discovered able to delay entry from G0 to S-phase [94]. All 
Bcl-2 proteins share so-called Bcl-2 homology domains (BH1-4) [95] important 
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for binding to each other and for the function of the proteins. Bcl-2 proteins are 
able to form homo- and heterodimers eventually leading to the formation of pores 
within the mitochondrial membrane [96, 97]. The decision of pro- or anti-
apoptotic is made by the relative ratio of the different Bcl-2 family members. Bcl-
2 and Bcl-Xl are antiapoptotic, Bcl-2 associated X protein (Bax), Bcl-2 
antagonist/killer (Bak), Bad, Bim and BH3 interacting domain death agonist (Bid) 
are some members of the pro-apoptotic part of the family. Bid and Bad (BH3 only 
proteins) miss the C-terminal transmembrane domain and are found in the 
cytoplasm.  
Bid is a target for the `extrinsic´ caspase 8 and after cleavage through the caspase 
to the truncated form (tBid), it reveals a Bcl2 homology domain (BH3) for 
dimerisation and a hydrophobic core thought to be important for membrane 
association on mitochondria [98, 99]. Upon its cleavage, it translocates to 
mitochondria and it leads to apoptosis induction by inducing oligomerisation of 
Bax and permeabilisation of the mitochondrial outer membrane (also called 
mitochondrial apoptosis inducing channel, MAC) [100]. Bcl-2 can antagonise this 
event by binding Bax [97]. Due to its function, Bid contributes to a possible 
crosstalk of the extrinsic and intrinsic pathway. 
Bad has been shown to be phosphorylated by protein kinase B/Akt, protein kinase 
A and c-Raf/Raf 1 [101]. This phosphorylation inactivates the protein and 
prevents dimerisation and antagonising Bcl-2 or Bcl-Xl [102].  
Bcl-2 proteins take part in inducing cytochrome c release from mitochondria and 
thus apoptosome formation and caspase 9 activation. If the formation of MAC is 
the main reason for cytochrome c release, or if it only leads to mitochondrial 
swelling and membrane rupture is still discussed [103].  
The overexpression of Bcl-2 in haemapoietic cell lines leads to increased 
insensitivity in these cells to many cytotoxic substances [104-108]. In this study, 
stable transfectants of Jurkat cells overexpressing Bcl-2 and the Jurkat vector 
control cells were used (a gift from H. Walczak (Heidelberg, Germany)) to 
evaluate if they show similar resistance to MC induced cytotoxicity.  
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Fig. Overview:  apoptosis pathways (for further details see text). 
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3.4  Mitochondria and the permeability transition pore 
 
Mitochondria not only play an important role for energy metabolism, Ca2+ 
homeostasis and ROS production of the cell (also important for the regulation of 
physiological processes), but they are key regulators of cell death pathways (see 
chapter 3.1).  
During apoptosis, mitochondrial membrane integrity is abolished by multiple 
mechanisms and the permeabilisation of the outer mitochondrial membrane is 
thought to be a crucial event during early apoptosis [109] leading to cytochrome c 
release and activation of caspases (see chapter 3.1). 
Aside from the concerted action of propapoptotic Bcl-2 proteins on the 
mitochondrial outer membrane (see chapter 3.3), another model for membrane 
permeabilisation in mitochondria has been proposed: the permeability transition 
pore (PTP) [110, 111] (see Fig.). 
Permeability transition is an event leading to the permeability of the inner 
mitochondrial membrane to molecules up to 1500 Da. This is achieved by the 
opening of a dynamically regulated pore, the PTP. In the fully open state it 
probably has a pore diameter of 3 nm [112]. This pore was shown to be voltage-
dependent and cyclosporin A (CsA) sensitive and had high conductance. It 
consists of many different proteins which, under normal conditions, have their 
own important functions in the cell, but under conditions favouring apoptosis act 
together to mediate mitochondrial cell death. Constituents are in/on the outer 
mitochondrial membrane: the voltage dependent anion channel (VDAC), the 
peripheral type benzodiazepine receptor, Hexokinase and Bcl-2 proteins. In/on the 
inner membrane the adenine nucleotide transporter (ANT), creatine kinase and 
cyclophillin D (the target of CsA) can be found. Several modulators can increase 
or decrease the open probability of the PTP (summarised in Fig. The permeability 
transition pore) leading to an decrease in the membrane potential (∆Ψm), loss of 
the proton gradient important for ATP-synthesis by ATP-Synthase and general 
equilibration of ion gradients and other molecules with less than 1500 Da. 
Especially this equilibration of ions leads to mitochondrial swelling by influx of 
water, causing mechanical membrane disruption which then could be responsible 
for release of larger molecules from mitochondria (e.g. cytochrome c). 
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Fig. The permeability transition pore [111]. PBR = peripheral benzodiazepine receptor, HK = 
Hexokinase, CK = Creatinkinase, VDAC = voltage dependent anion channel, ANT = adenine 
nucleotide transporter, CypD = cyclophillin D, OM = outer membrane, IM = inner membrane. 
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4 Cell cycle 
One prominent defect in tumour cells is the deregulation of the cell cycle leading 
to uncontrolled proliferation. Many cell cycle regulators are altered in cancer 
cells, in most cases resulting in a deregulation of phase G1 progression where the 
decision between proliferation and quiescence is made [113].  
In 1951, the cell cycle was first described by Howard and Pele. It consists of 
several phases which are controlled by many regulatory proteins. The most 
important of them are cyclins, cyclin-dependent kinases (Cdks) and the tumour 
suppressors p53 and pRb. The cell cycle checkpoint or tumour suppressor protein 
p53 is one component of the cell cycle which is altered in cancer cells [114], also 
for example in HL60 cells (see section below). It has an N-terminal transcriptional 
activation domain and a dimerisation domain at the C-terminus. Its function is to 
arrest cells in G1 phase after genotoxic damage in order to allow DNA repair or, if 
DNA damage is beyond repair, to induce apoptosis. The antiproliferating effect is 
mediated by the expression of the Cdk inhibitor p21 [115]. Another regulator of 
the cell cycle is the retinoblastoma protein pRb [116]. Although its function is still 
not totally clarified, its phosphorylation plays a role [117]. pRb acts as a master of 
regulation of transcription [118] and interactions between p53 and pRb are 
possible [119]. It is thought that pRb is first hypophosphorylated and inhibits 
transcriptional activity of the transcription factor E2F. Upon phosphorylation 
(probably cyclin/cdk dependent) some hours before DNA synthesis is first 
detectable, phosphorylated pRb releases E2F and G1 progression to S-phase can 
take place [120-122]. The interaction between pRb and E2F also has a regulatory 
effect on genes of apoptosis regulation. 
Cyclins are key regulators of cell cycle progression. They are 56kDa proteins and 
regulatory subunits of the Cdk-complexes. These complexes activate their targets 
by phosphorylation rendering effects like cell cycle progression in general (see 
Fig. 1), chromatin remodelling and microtubule formation. Their expression is 
also regulated by the NFκB family of transcription factors [123].  
In the present study, an effect of MC on the cell cycle was at first excluded since 
HL60, promyeloid leukemian cells, have no or only fragments of p53 (see section 
below). However, this topic was then further explored since MC reduced the cell 
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number of Jurkat T-lymphocytes deficient in caspase 9, although apoptosis 
induction was abolished. 
 
 
 
Fig. Cell cycle control [124](explanation see text). Cdk = cyclin dependent kinase, Rb = 
retinoblastoma protein, E2F = transcription factor. 
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5 Cells 
5.1 HL60 
The HL60 cell line was established from the blood of a female patient with acute 
myeloid leukaemia (AML) in 1977 [125]. These cells are mainly promyelocytes 
with a block of differentiation but are able to differentiate upon varying stimuli 
into granulocytes (DMSO, actinomycin D, retinoic acid) or 
monocytes/macrophages (phorbol esters, vitamin D3, sodium butyrate) [126, 127]. 
After isolation from the patient, cells were transferred into the appropriate 
medium leading to the development of a growth-factor independent immortal cell 
line growing in suspension with a doubling time of 20 to 45 hours. Over the years, 
intensive studies were done with these cells leading to the findings that the p53 
gene is largely deleted [128], the gene of the small G protein N (neuroblastoma)-
Ras is mutated in codon 61 [129] and the gene for the transcription factor c-Myc 
is amplified up to 30-fold [130]. All these properties make HL60 cells the ideal 
candidate to study the mechanism of differentation of stem cells and to use them 
in the study of MAPK pathways. In this study we used HL60 mainly for two 
reasons. First, we tried to find out the targets of MC for apoptosis induction in 
leukaemian cells and HL60 are useful as a leukaemian cell line, since, due to the 
lack in p53, they allow to exclude this pathway of apoptosis induction. Second, 
HL60 are also useful for a direct comparison with healthy granulocytes. 
 
5.2 MM6  
Mono-Mac-6 (MM6) are monocytic cells isolated in 1985 from the blood of a 64 
year old man with acute monocytic leukemia (AML). They are round cells 
growing in suspension or sometimes loosely adhering, have a doubling time of 
around 48 h and about 1-5% of the cells are multi-nuclear giant cells. MM6 were 
shown to have the same phenotype as mature monocytes [131]. In this study, 
MM6 were used to test the apoptosis-inducing properties of MC. As control cell 
line for MM6 we used peripheral blood mononuclear cells (PBMC) from the 
blood of healthy donors. 
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5.3 Jurkat T-lymphocytes 
Jurkat T-lymphocytes were established in 1977 from the blood of a 14 year old 
boy with acute lymphoblastic leukemia (ALL) [132]. They represent an 
immortalised cell line for the study of acute T cell leukemia and T cell signaling. 
They are round cells growing in suspension with a doubling time of around 25 to 
35 hours. In the present investigation, differently modified Jurkat cells were used 
to study the apoptosis inducing effect by MC concerning the intrinsic and 
extrinsic pathway. 
5.4 Neutrophilic granulocytes  
Neutrophilic granulocytes constitute 50-60% of total blood cell number in the 
peripheral blood. They are the first line of defense against pathogens or 
exogenous `non-body´ substances intruding into the organism [133]. Usually, 
neutrophils are contained in the circulating blood. Upon inflammatory events, 
chemoattractants lead to the invasion of neutrophils into the area of inflamed 
tissue. This invasion starts with low affinity contact of neutrophils to the 
endothelium (rolling), sticking to the blood vessel wall (mediated by integrins, 
CD11/CD18 and ICAMs, intercellular adhesion molecules) and then migration 
through cell-cell junctions into subendothelial space. When reaching the site of 
inflammation, they start the production of ROS (by membrane associated 
NADPH-oxidase) [134] or NO (by NO-synthase) [135] and release the contents of 
their granules. The granules can be divided into azurophilic (primary), specific 
(secondary) and gelatinase granules (tertiary) [136]. These contain mostly 
proteolytic enzymes (catepsins, lysozyme, gelatinase) but also receptors and 
surface markers (fMLP receptor, CD 11). By these mechanisms, pathogens can be 
eliminated within only hours, so they are a hallmark of acute immune response. 
In the present work polymorphonuclear leukocytes (PMNL) represented an 
suitable system to test signaling pathways affected by MC and to compare these 
cells to the leukemian cell line HL60. We obtained neutrophils together with other 
granulocytes in the PMNL fraction of buffy coats prepared from human blood. 
Since the life span of neutrophil granulocytes is only about 12 hours, they were 
not used for experiments concerning apoptosis or for other experiments requiring 
longer stimulation/incubation times. 
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5.5 Mononuclear cells (PBMC) 
Apart from the granulocyte fraction isolated from buffy coats, also the 
lymphocytic/monocytic fraction termed peripheral blood mononuclear cells 
(PBMC) was used in this work. This fraction contains lymphocytes (T- and B-
lymphocytes, constituting about 20% of the white blood cells) as well as natural 
killer (NK) cells and monocytes/macrophages. They all have a defined nucleus 
and are the part of the immune system especially involved in the adaptive immune 
response (T- and B-cells).   
 
 
 
Fig. Overview: haematopoiesis [137]. HSC = haematopoietic stem cell, HPC = haematopoietic 
progenitor cell , CLP = common lymphoid progenitor, CMP = common myeloid progenitor, CFU-
GEMM = colony forming unit – granulocytes erythrocytes monocytes megakaryocytes, CFU-GM 
= colony forming unit-granulocytes monocytes. 
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6 G protein coupled receptor pathways 
One large group of agonist-activated receptors of the cell is the class of the G 
protein coupled receptors (GPCRs). They are membrane-spanning heptahelical 
structures with three extracellular and three intracellular loops [138, 139]. The N-
terminus is located outside the cell, the C-terminus inside. Upon binding of an 
agonist, the receptor changes its conformation and this leads subsequently to an 
activation of an associated G protein, a small trimeric protein with intrinsic 
GTPase activity. For this activation mainly the second and third intracellular loops 
are responsible [139]. In the inactivated state, the α subunit of a G protein binds 
GDP. Upon activation GDP is exchanged in a rate limiting step by GTP [140, 
141]. The α/β/γ-complex of the G protein disassembles and α or β/γ subunits then 
effect different targets such as phospholipases (PLCβ, PLD), adenylate cyclase 
(AC) and many others. One prototype receptor in human myeloid cells is, for 
example, the formyl peptide receptors (FPRs) with associated Gi proteins whose 
β/γ subunits target PLC-β [142]. The inactivation of the G protein is achieved by 
the action of the GTPase activity of the α subunit [140, 143]. GTP is degraded to 
GDP and inorganic phosphate and the α subunit reassembles with the β/γ subunit. 
 
6.1 Downstream targets of the FPR 
Human neutrophils and HL60 possess FPRs, LTB4 and PAF receptors. 
Neutrophilic granulocytes are specialised on the destruction of microorganisms. 
They possess cellular mechanisms capable to react to pathogen intruders by 
detecting, moving towards them and killing them, e.g. by ROS and protease 
release. These events are triggered by substances that bind to GPCRs and since 
their binding results in chemotaxis they are also referred to as chemoattractants 
[144, 138]. The small peptide fMLP derived from bacteria or produced 
endogenously in mitochondria, for example, induces Gi-dependent (PT-sensitive) 
[145, 146] Ca2+ release from intracellular stores, activation of NADPH oxidase 
leading to ROS formation [147], azurophilic granule release [148] and regulation 
of selected K+-channels [149]. The release of granule contents includes cathepsin 
G, proteinase-3 and elastase. All these serine proteases play a role in degradation 
of the extracellular matrix or digesting pathogens at the sites of inflammated 
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tissue. Aside from involving Gi-proteins it is also stated that Gq-proteins might 
play a role in these events [150, 151].  
Phospholipase C-β (PLC-β) lies downstream of the FPR. It is activated either by 
the β/γ subunit of Gi [152, 142] or the α subunit of Gq [153]. This PL leads to 
cleavage of phosphatidyl inositol bisphosphate (PIP2) to diacyl glycerol (DAG) 
and inositol trisphosphate (IP3), that triggers for Ca2+ release [154]. PLC 
activation is one of the earliest events after fMLP stimulation [155]. DAG, a 
phorbol ester is able to activate PKC together with Ca2+. PKC is probably 
responsible for ROS formation and influences the cytoskeleton by myristoylated 
alanine-rich C kinase substrate (MARCKS) [156, 157]. It furthermore activates 
Ras or Raf directly, thus, signaling towards the MAPK pathway [158].  
LTB4 and PAF receptors are thought to act in the same manner as FPRs in 
differentiated HL60 and PMNL. When activated, they lead to increased [Ca2+]i 
but are not or less able to cause azurophilic granule release and  ROS formation 
[159, 160]. LTB4 acts on the LT receptors BLT1 and 2 [161] and PAF on the PAF 
receptor. Both receptors are coupled to Gi and Gq proteins. 
 
 
Fig 6. Downstream targets of the fMLP receptor FPR. 
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7 The MAPK pathways 
The family of mitogen activated protein kinases (MAPK), also sometimes referred 
to as microtubule associated protein kinases, are serine/threonine specific kinases 
responding to extracellular stimuli, leading the signal on towards gene expression, 
cell proliferation and survival. There are three main groups of MAPK: a) the 
extracellular signal-regulated kinases 1 and 2 (ERK 1/2) being normally activated 
by growth factors and regulate growth, proliferation and differentiation [162], b) 
c-Jun N-terminal kinases (JNKs), also termed stress-activated protein kinases 
(SAPK) [163] and c) p38 MAPK [164]. JNK and p38 MAPK are stimulated by 
stress factors such as heat, osmotic shock, cytokines and radiation and having an 
influence on differentiation and survival/apoptosis. 
Activation of the MAPK pathway usually involves receptor tyrosine kinases. 
These receptors are autophosphorylated before other kinases and adaptor proteins 
can bind the phosphorylated tyrosine residues or proline-rich domains via the src 
homology domains 2 and 3 (SH2, SH3), respectively [165].  The next component 
downstream is the growth factor receptor bound protein 2 (Grb2) which transfers 
the signal to the guanine nucleotide exchange factor (GEF) son of sevenless (Sos). 
This exchange factor is responsible for activation of a member of the Ras family 
of proteins. Ras can transmit the signal by phosphorylation of a MAPKKK which 
is then signaling downstream to a MAPKK that phosphorylates (and thus 
activates) MAPK itself. 
The Ras (rat sarcoma) oncogenes are a family of small G proteins. Their genes 
were first identified in rats by Harvey [166] and Kirsten [167] (K-ras, H-ras and 
N-ras). There are more than one hundred proteins in the Ras superfamily. In the 
present study, an antibody was used detecting total  protein amounts of K-Ras, H-
Ras and N-Ras, the Ras isoforms signaling towards gene expression concerning 
cell proliferation. Mutation of ras, resulting in impaired GTPase activity or in 
guanine nucleotide exchange, can lead to increased Ras activity being the reason 
for many carcinogenic cell transformations (see also HL60). Downstream of Ras 
there is the serine/threonine-specific kinase Raf (rat fibrosarcoma or rapidly 
growing fibrosarcoma). C-Raf or Raf 1 is similar in sequence to A-Raf and B-Raf 
but Raf 1 is the Raf isoforms signaling from Ras towards MEK 1/2 [168]. Aside 
from Raf 1, MEK 1/2 (MAPKK/MAP2K) is phosphorylated by a MAPKKK 
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(MAP3K/MEKK). Upon activation, MEK1/2 then in turn 
phosphorylates/activates ERK 1/2 [169].  
Recent findings report that there are two scaffolding proteins involved in 
downstream processing of the signal from Ras towards ERK: kinase supressor of 
Ras (KSR) and connector enhancer of KSR (CNK) [170]. The theory bases on the 
assembly of a complex at the membrane consisting of Ras, c-Raf, KSR and CNK 
leading together to phosphorylation of MEK 1/2 and subsequently ERK [171, 
172](see Fig. Complex formation model for MEK and ERK activation). 
 
 
Fig. Complex formation model for MEK and ERK activation [171, 172] 
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7.1 Activation of the Ras/Raf pathway by fMLP 
The small G protein Ras is one possible target of the FPR-associated Gi protein. 
Intensive studies have been conducted on the connection between the classical 
GPCR pathways and the MAPK pathways [173, 174, 158]. It was found, that 
fMLP induces Raf, MEK-1 and ERK1/2-activation after 30 sec and that this 
activation reached a maximum after 2-3 min. Interestingly, pertussis toxin, a 
classical Gαi inhibitor, reduced fMLP induced Raf activation, but only to around 
65 to 80%. This means that there must exist at least two possible ways of 
activating Raf. Another study stated Raf being activated by PKC [175]. 
Nonetheless, this pathway is not used when stimulating neutrophils with fMLP. 
Raf activation in fMLP stimulated neutrophils was not affected when PKC was 
inhibited by 2 µM GF109203x for 0.5 to 5 min, while PMA activation of Raf 
could be inhibited by GF. Aside from a direct interaction of Gi with Ras, there is 
the possibility of the involvement of tyrosine kinases which are usually activated 
by RTKs such as the EGF receptor. They transfer the signal from the GPCR 
towards the Ras/Raf pathway [176-178]. This process is called transactivation and 
is an excellent example for the intertwined activation events of signaling cascades. 
As example, Worthen  et al. showed that fMLP-induced Raf activation can be 
inhibited by the tyrosine kinase inhibitor herbimycin A (thought to be most 
specific for Src-kinases) and thus, that activation of Raf by fMLP is dependent on 
tyrosine kinases. Recently, MEKK1, another upstream kinase of the MAPK 
pathway, has been identified [179] and might present an additional way of 
activating MEK and ERK. Taken together, in fMLP-induced Ras/Raf activation 
the direct interaction of Gαi with Ras is the fastest and most prominent event 
leading to ERK activation. Activation of Raf by PMA-stimulated PKC is also 
possible, albeit of no importance in fMLP-stimulated neutrophils. 
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Fig. Pathways of ERK-activation by fMLP and PMA [158]. 
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8 Aim of the study 
It was shown that myrtle extracts and MC have strong anti-inflammatory effects 
[180, 18]. In the course of the studies concerning MC and its effects on 
inflammation it was found that MC can activate caspases [22]. Since nowadays 
the connection between inflammation and cancer is strongly emerging, the 
research was continued in the direction of apoptosis induction by MC in cancer 
cells. Initial experiments in cancer cells showed that MC indeed reduces cell 
viability most efficiently in cells of leukaemian origin and that untransformed 
control cells (PBMC) are hardly susceptible to MC [22]. 
The aim of the present study was to identify and to characterise the exact 
mechanisms of apoptosis induction by MC. This was no easy task since many 
details about apoptosis and how it is induced are still missing or not totally 
understood.  
To put the cart before the horse, this work begins with explaining the late effects 
of apoptosis like caspase cleavage, DNA fragmentation, cytochrome c release and 
the differentiation between intrinsic and extrinsic way of apoptosis induction. 
Then it was the aim to explain the imminent events preceding these effects. 
On the other hand it was important to consider previous data obtained by C. Feißt 
and colleagues which showed some short-term effects of MC in non-degenerated 
PMNL [18]. It was also important to understand these mechanisms of interference 
with signaling pathways in granulocytes and comparing them with the ones 
observed in the cancerogenous counterpart HL60. Here, we see the possible 
mechanistic fundament which then might lead to apoptosis induction in cancer 
cells. In the end, the study tries to give a theory why this interference renders 
apoptosis induction in cancer cells but not so in non-transformed cells, going 
deeply into detail about differences in signaling pathways and metabolic 
circumstances in non-transformed cells versus cancer cells. 
The data presented in this work will show that MC has selective apoptotic effects 
on cancer cells and the respective mechanisms. Taking into account that MC also 
possesses potent anti-inflammatory effects (and the presumed link between 
inflammation and cancer), MC is proposed an efficient and selective drug with 
high therapeutical potential in leukaemia and inflammatory diseases, worth to be 
tested in pre-clinical animal studies for further development.
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Materials and Methods 
54 Materials and Methods 
Materials and Methods 
 
9 Materials 
 
Myrtucommulone (MC) was isolated from myrtle leaves as described previously 
[1] and obtained from Dr. Appendino, Naples, Italy and Dr. J. Jauch, Saarbrücken, 
Germany. MC stocks were prepared at 15 mM in DMSO and kept in the dark at -
20°C. Freezing-thawing cycles were kept to a minimum. 
 
The following materials were obtained from: 
2´,7´-dichlorofluorescin diacetate (DCFH-DA), SIGMA-Aldrich, Germany 
5,5′,6,6′-Tetrachloro-1,1′,3,3′-tetraethylbenzimidazolocarbocyanine iodide 
(JC-1), SIGMA-Aldrich, Germany 
5-bromo-4-chloro-3-indolylphosphate toluidine salt (BCIP), Applichem 
5-HETE (5-hydroxyeicosatetraenoic acid), Cayman Chemical, Tallinn, Estonia 
Arachidonic acid (AA), Biomol, Hamburg, Germany 
β Actin-antibody, Santa Cruz 
BWA4C was a generous gift from Dr. L. G. Garland (Wellcome Research 
Laboratories) 
Carboynl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP), SIGMA-
Aldrich, Germany 
Caspase 8 antibody (mouse), Prof. Wesselborg, University Hospital, Tübingen 
Chelerythrine, SIGMA-Aldrich, Germany 
Cycloheximide (CHX), SIGMA-Aldrich, Germany 
Cyclosporine A (CsA), Calbiochem 
Daunorubicin, Biomol Intern., USA 
Fas-Ligand, Biozol, Eching, Germany 
GSH-Sepharose beads, GE Healthcare, Freiburg, Germany 
HybondTM-C Extra nitrocellulose membrane, GE Healthcare  
Ionomycin, SIGMA-Aldrich, Germany 
Leukotriene B4, Biozol, Eching, Germany 
Leupeptin, SIGMA-Aldrich, Germany 
N-formyl-methionyl-phenylalanine (fMLP), SIGMA-Aldrich, Germany 
Nitro-blue tetrazolium chloride (NBT), Roche 
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peQGold Protein-Marker IV, PeQLAB Biotechnology, Erlangen, Germany 
pGEX-Raf-ras binding domain, Frankfurt 
Phenylarsine oxide (PAO), SIGMA-Aldrich, Germany 
Phenylmethylsulfonylfluorid (PMSF), SIGMA-Aldrich, Germany 
Phorbol 12-myristate 13-acetate (PMA), Alexis Biochemicals, Lausen, 
Switzerland 
p-nitrophenyl phosphate (pNpp), Applichem 
Primary antibodies, New England Biolabs 
Propidium iodide (PI), SIGMA-Aldrich, Germany 
phospho-tyrosine antibody, Santa Cruz 
Q-VD-Oph (QVD), Calbiochem 
Roti-Nanoquant, Roth, Heidelberg, Germany 
Secondary antibodies, SIGMA-Aldrich, Germany 
Soybean trypsin inhibitor (STI), SIGMA-Aldrich, Germany 
Staurosporine, Calbiochem, Germany 
Thiazolyl blue tetrazolium bromide (MTT), SIGMA-Aldrich, Germany 
Vybrant Apoptosis Kit #2, Molecular Probes, Invitrogen 
 
Chemicals not listed were obtained from SIGMA-Aldrich, Germany or Roche 
Diagnostics, Germany. 
 
Cell culture and preparation materials were obtained from: 
RPMI 1640 medium, PAA, Coelbe, Germany 
penicillin/streptomycin 100x , PAA, Coelbe, Germany 
fetal calf serum (FCS), PAA, Coelbe, Germany 
1 M Hepes, PAA, Coelbe, Germany 
MEM non-essential amino acids, SIGMA-Aldrich, Germany 
Lymphocyte Separation medium, PAA, Coelbe, Germany 
 
Cell culture flasks, petridishes, 96-well, 12-well plates and other steril cell culture 
materials were obtained from Greiner Bio-One, Germany. 
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10 Cells 
 
Jurkat-A3 cells, caspase-8-deficient Jurkat cells, and FADD-deficient Jurkat cells 
were provided by Dr. John Blenis, Boston, MA; caspase-9-deficient Jurkat cells 
and caspase-9-deficient Jurkat-caspase-9-retransfected cells were obtained from 
Prof. Dr. Klaus Schulze-Osthoff, Duesseldorf, Germany; HL-60 (acute 
promyelotic leukemia), Jurkat (acute T-cell leukemia) and Jurkat DD3 (acute T-
cell leukemia, Fas-deficient), were obtained from the American Type Culture 
Collection (ATCC). Mono Mac 6 (MM6, acute monocytic leukemia) cells were a 
kind gift by Dr. H.W. Ziegler-Heitbrock, Muenchen, Germany.  Jurkat vector 
cells and Jurkat Bcl 2-wt (Bcl2 overexpressing Jurkat cells) cells were obtained 
from the lab of  Dr. Claus Belka, University Hospital, Tuebingen. 
PBMC and PMNL were freshly isolated from leukocyte concentrates derived 
from human healthy donors obtained from the Blood Center at Tuebingen 
University Hospital. In brief, venous blood was taken from healthy adult 
volunteers and subjected to centrifugation at 4,000 × g for 20 min at 20°C for 
preparation of leukocyte concentrates. Cells were promptly isolated by dextran 
sedimentation and centrifugation on Lymphoprep cushions (PAA Laboratories). 
After washing in PBS pH 7.4, PBMC were resuspended in RPMI 1640 medium 
with supplements. PMNL were taken from the pellet and hypotonic lysis of 
remaining erythrocytes was performed as described [181]. 
All cells were cultured in respective media supplemented with 10% fetal calf 
serum (FCS, PAA, Coelbe, Germany), 100 µg/ml streptomycin and 100 units/ml 
penicillin and grown at 37°C in a 5% CO2/ 95% air atmosphere. For harvesting, 
cells were centrifuged at 200 × g for 10 min at RT and finally resuspended as 
indicated. 
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11 Methods 
11.1 Cytotoxicity assay (trypan blue) 
 
Cells were incubated at 0.2 × 106 cells per ml in the appropriate medium with 
compounds or vehicle (DMSO) for the indicated times. Cells were harvested by 
centrifugation at 1200 rpm for 10 min at room temperature, washed with PBS and 
counted under a light microscope using a “Bürker” hemocytometer after addition 
of trypan blue (1:1, vol/vol; 0.2% trypan blue in 0.9% NaCl). Since trypan blue is 
a cell impermeable dye staining chromatin, dead cells appeared blue under the 
microscope, therefore, the cell viability could be determined by counting only 
viable cells.  
11.2 Cytotoxicity assay (MTT assay) 
 
Cell viability was assessed using the MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay [182] as described before [183]. In brief, cells 
were incubated at 37°C and 5% CO2 atmosphere with the indicated compounds 
for the times indicated. DMSO was used as solvent for all compounds (never 
exceeding 0.5% (vol/vol)). Then, MTT reagent was added for a minimum of 3 
hours or until untreated control cells clearly showed blue staining. Afterwards, 
100 µl SDS lysis buffer (10% SDS in 20 mM HCl, pH 4.5) was added and cells 
were left on the shaker for 16-20 hours. Plates were read on a multiwell scanning 
spectrophotometer (Victor3 plate reader, PerkinElmer) at a wavelength of 595 nm. 
Induction of cell death was determined as the relative reduction of the optical 
density compared to DMSO treated and EtOH treated cells. 
The MTT assay is based on the reduction of the yellow tetrazolium bromide to a 
non-hydrolysable purple formazan. This reduction is accomplished by enzymes of 
mitochondria (succinate-dehydrogenases) and endoplasmatic reticulum and 
probably depends on NADH and NADPH. Therefore, only metabolic active, 
viable cells are able to reduce the MTT. However, it is important to note that 
reduction in cell viability measured by MTT assay can be due to decreased cell 
proliferation, increased apoptosis and/or necrosis or due to reduction in metabolic 
activity of cells. 
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11.3 Determination of DNA-fragmentation and cell cycle 
measurements 
 
According to the method developed by Nicoletti [184] nuclei of apoptotic cells 
were stained with propidium iodide to determine DNA-leakage taking place after 
DNA-fragmentation during apoptosis. In brief, 0.3 × 106 cells were incubated in 
the appropriate medium with DMSO, MC and controls in the amounts and for the 
times indicated. After incubation, cells were harvested by centrifugation at 4,200 
g for 5 min at RT and washed once with PBS. The pellet was then resuspended in 
100 µl hypotonic PI-lysis buffer (0.1% sodium citrate, 0.1% Triton X-100, 50 
µg/ml propidium iodide) and incubated in the dark for 10 min at RT. Then, 
fluorescence intensity was measured using a FACScalibur (Becton Dickinson) 
flow cytometer (FL2) and was plotted logarithmically vs. cell counts. 
To better evaluate cell numbers in G1, S and G2 phase, fluorescence intensities as 
measured in FL3 were plotted linear vs. cell counts. The fluorescence intensity of 
nuclei from non-apoptotic diploid cells was set to around 103 in FL2 channel 
(585/42). The method is based on hypotonic rupture of cellular membranes to 
allow PI to enter the cells and the nuclei. Nuclei of apoptotic cells have lower 
fluorescence intensities due to the leakage of DNA-fragments during apoptosis, 
visualised as a hypodiploid peak (subG1). 
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Histogram of mainly apoptotic nuclei(FL2).          Histogram of different cell cycle phases(FL3). 
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11.4 Measurement of cytochrome c release from 
mitochondria 
 
Cells were seeded at 4 × 106/ml culture medium and incubated with the test 
compounds or vehicle (DMSO). After 24 hours cells were harvested, washed once 
in PBS and 107 cells were resuspended in 200 µl PBS. In order to permeabilize 
cellular membranes, 600 µg/ml (300 µg/ml for Jurkat cells) digitonin was added 
and immediately vortexed for 10 seconds, incubated for another 30 seconds at RT 
and centrifuged at 20,000 × g at 4°C for 1 min. The supernatants (cytosolic 
fractions) were transferred to new tubes and mixed 1:1 (vol/vol) with 5% 
trichloroacetic acid. Precipitation of cytosolic proteins was performed at 4°C 
overnight. Proteins were pelleted by centrifugation at 20,000 × g at 4°C for 30 
minutes and resuspended in 25 µl PBS. Aliquots of 5 µl were used for 
determination of protein concentration using Roti-Nanoquant (Roth, Karlsruhe, 
Germany). Equal amounts of protein were mixed 1:1 (vol/vol) with 2 × 
SDS/PAGE sample loading buffer and analyzed for cytochrome c by SDS-PAGE 
and Western Blot using an anti-cytochrome c antibody. 
Digitonin dissolves cholesterol from the plasma membrane but leaves the 
membranes of intracellular organelles intact. By permeabilisation of the plasma 
membrane and subsequent centrifugation it is possible to separate cytosolic 
proteins from proteins contained in the organelles. This way, cytochrome c which 
is normally found within mitochondria should only be detected in the cytosol 
upon previous cytochrome c release due to apoptotic events. 
 
 
11.5 Determination of the mitochondrial membrane 
potential ∆Ψ 
 
Cells (106 per ml) were incubated in culture medium with solvent (DMSO), MC 
and controls as indicated. After incubation, 0.75 µg/ml JC-1 was added to the 
cells and incubated 15 min at 37°C. Then, cells were harvested, washed once with 
ice cold PBS and kept on ice until measuring red/orange against green 
fluorescence was analysed by flow cytometry, where JC-1 was excited at 488 nm. 
Red/orange fluorescence was detected through FL2 (575 nm) and green 
fluorescence through FL1 (530 nm). A log FL1 (x-axis) versus log FL2 (y-axis) 
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dot blot was created. The percentage of cells that lost ∆Ψm versus cells possessing 
∆Ψm was calculated using the cellQuest software.   
JC-1 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethyl 
benzimidazolyl carbocyanine iodide (JC-1) is a 
substance which enters the cell and attaches to 
mitochondrial membranes. Depending on the 
membrane potential it either is a green fluorescent 
monomer (at low potentials) or forms red/orange 
fluorescent aggregates at higher potentials. The 
ratio of red/orange to green fluorescence is only dependent on the potential and 
not on the size or shape of mitochondria.  
 
5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolylcarbocyanine iodide (JC-1) 
 
 
11.6 Annexin V / propidium iodide assay 
 
One event during early apoptosis is the externalization of the phospholipid 
phosphatidylserine (PS). Under normal conditions, PS is located to the inner layer 
of the plasma membrane. Upon apoptosis stimulation it is flipped to the outer 
membrane and functions as signal for macrophages to bind and ingest the 
apoptotic cell.  
Annexin V, a coagulation protein that binds to PS Ca2+-dependently, is an 
important modulator of phagocytosis of apoptotic cells [185]. This phenomenon 
has been used to develop a method using fluorophore-coupled Annexin V and 
another membrane impermeable dye such as propidium iodide (PI) staining DNA 
to discriminate between viable, apoptotic, necrotic and late apoptotic cells [186]. 
Not only externalised PS can be bound by Annexin V but also during late 
apoptosis and necrosis when cell membrans are disrupted, AnnexinV can enter the 
damaged cells and can bind PS from the inside. To distinguish between these two 
possibilities of Annexin V binding and therefore distinguish early apoptosis from 
late apoptosis and necrosis, also propidium iodide is used which only enters the 
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cell and stains DNA when membranes are disrupted. The Vybrant Apoptosis Kit 
#2 (Molecular Probes, Invitrogen) was used and instructions were as follows: 
0.2 × 106 cells per ml were incubated with DMSO, MC and controls in the 
appropriate medium for the times and in concentrations indicated. Then, about 4 ×  
105 cells were harvested, washed in cold PBS and resuspended in 100 µl 1 × 
annexin binding buffer. Then 3 µl annexinV-Alexa Fluor 488 and 1 µl PI working 
solution prepared as described in the Kit protocol were added and samples were 
measured as soon as possible in a FACScalibur flow cytometer (Becton 
Dickinson) (FL1 (530 nm) vs. FL3 (>575 nm)). 
necrotic/ late
apoptotic
apoptoticviable
 
   
 
       Dot plot of AnnexinV-AlexaFluor 488/ propidium iodide stained cells. 
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11.7 SDS-PAGE and Western Blot 
 
Cells (4 × 106) were resuspended in 50 µl PBS, mixed with the same volume of 2 
× SDS/PAGE sample loading buffer (SDS-b) (20 mM Tris-HCl, pH 8, 2 mM 
EDTA, 5% (m/vol) SDS, 10% (vol/vol) β-mercaptoethanol), and boiled for 5 min 
at 95°C. Aliquots (20 µl) corresponding to equivalents of 0.8 × 106 cells were 
mixed with 4 µl glycerol/0.1% bromphenol blue (1:1, vol/vol) and proteins were 
separated by SDS-PAGE. After electroblotting to nitrocellulose membrane (GE 
Healthcare) and blocking with either 5% non-fat dry milk or 5% bovine serum 
albumin for 1 h at room temperature, membranes were washed and incubated with 
primary antibodies overnight at 4°C. The membranes were washed and incubated 
with 1:1000 dilution of alkaline phosphatase-conjugated immunoglobulin G for 3 
hours at room temperature. After washing, proteins were visualized with nitro 
blue tetrazolium (NBT) and 5-bromo-4-chloro-3-indolylphosphate (BCIP).  
 
 
11.8 PTPase assay 
 
PTPase activity was measured as described previously [187]. In short, cells were 
set to 2 × 106 per ml in PBS + 0.1% glucose + 1 mM CaCl2. DMSO, MC and 
phenylarsine oxide (PAO) were added to about 8 × 105 cells and samples were 
incubated for 30 min on ice. After centrifugation at 2,000 × g for 5 min and 4°C, 
pellet was carefully resuspended in 20 µl Tris/KCl/MgCl2 (TKM) buffer + Triton 
X-100 (50 mM Tris, pH 7.4, 25 mM KCl, 5 mM MgCl2, 1 mM EGTA, 1 mM 
PMSF, 60 µg/ml STI, 10 µg/ml, 0.5% Triton X-100) and lysed for 15 min on ice. 
Cell lysates were obtained by centrifugation at 21,000 × g for 15 min. Since 
Triton disturbs the photometrical measurement of PTPase activity, the supernatant 
was diluted 1:10 in TKM buffer without Triton X-100. For each sample 100 µl 
was given into a 96 well plate and mixed with 20 µl 60 mM PTPase substrate p-
nitrophenyl phosphate (p-NPP). Absorption was measured over the time at 405 
nm in a Victor3 plate reader (PerkinElmer). 
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11.9  Ras-assay 
 
Ras activity was assessed by measuring the amounts of GTP-bound Ras using an 
affinity chromatographic method as described previously [188]. Briefly, 106 
PMNL or 5 × 105 HL60 cells were preincubated with DMSO, MC and controls 
for 30 min at 37°C and then stimulated as indicated. Then, cells were lysed by 
addition of 100 µl 2 × lysis buffer (50 mM Tris-HCl, pH 7.4, 10% glycerol, 1% 
NP-40, 2.5 mM MgCl2, 200 mM NaCl, 60 µg/ml STI, 1 µg/ml leupeptin, 1 mM 
phenylmethylsulfonyl fluoride) at 4 °C for 10 min. Cellular debris was removed 
by centrifugation at 20,000 × g for 5 min, and supernatants were transferred to 
new tubes containing the Ras-binding domain of Raf-1 (Raf-1-RBD) coupled to 
GSH-Sepharose beads. An aliquot of each supernatant was reserved to determine 
total Ras expression by Western blot analysis. Following a 45 min incubation at 4 
°C, the agarose beads were centrifuged at 2,500 × g for 1 min, the supernatant was 
discarded, and the agarose beads were washed three times in 1 x lysis buffer (see 
above). Bound proteins were eluted by the addition of 25 µl of SDS loading 
buffer, loaded onto an SDS-PAGE gel, and total amounts of Ras-GTP were 
quantified by Western blot.  
The method is based on the fact that only the active GTP-bound form of Ras is 
able to bind the Raf-Ras binding domain (Raf-RBD). When immobilising this 
domain to Sepharose beads and bringing it together with cell lysates of different 
Ras-activation states, only Ras-GTP will bind to the beads and can be separated 
from the rest of the cellular proteins. 
 
 
11.10  Statistical analysis 
 
Statistical evaluation of the data was performed by one-way ANOVAs for 
independent or correlated samples followed by Bonferroni post-hoc tests. Where 
appropriate, student´s t test for paired and correlated samples was applied. A p 
value of <0.05 (*), <0.01 (**) or <0.001 (***) was considered significant. 
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12 Myrtucommulone induces apoptosis in various 
cancer cell lines 
12.1 MC induces cell death in different cancer cell lines 
Within the previous work of Dr. I. Tretiakova [22], the effect of MC on cell 
viability was assessed in various cancer cell lines and the respective EC50 values 
were determined (Tab. 1). Cells were grown for 5 days in presence of MC in the 
corresponding cell culture medium. Then, the yellow water soluble dye 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT) was added.  
 
 
Tab. 1 EC50 values of MC induced cell death in different cancer and non-cancer cell lines. 
(Data (except PMNL and PBMC) obtained by Dr. I. Tretiakova, Frankfurt) 0.3-0.5 × 106  cells 
were incubated in a microtiter plate with vehicle and increasing amounts of MC for 5 days (24 h 
for PMNL) in the appropriate medium. Then, the dye MTT was added to the cells and incubated 
for another 3 h until the untreated control clearly showed blue staining. MTT lysis buffer was 
added and the plate was left shaking 16-20 h overnight at RT. The absorption was measured at 
595 nm in a Victor™ plate reader. EC50 values were determined by approximate analysis of the 
graphs obtained by MTT assay.  Data are given as mean ± S.E.  
 
cell line       origin cell death,  
EC50 (µM) 
PC-3            androgen-independent prostate carcinoma 3.93 ± 0.54 
LNCaP androgen-dependent prostate carcinoma 8.86 ± 1.19 
KFR  rhabdomyosarcoma  7.07 ± 1.05 
HL-60          acute promyelotic leukaemia  3.26 ± 0.51 
MM6               acute monocytic leukaemia 3.11 ± 0.66 
H9 cutaneous T-cell lymphoma 3.56 ± 0.50 
DLD-1          colorectal adenocarcinoma 8.75 ± 1.02 
JURKAT acute T-cell leukaemia 4.01 ± 0.52 
HFF human foreskin fibroblasts > 20 
PMNL polymorphonuclear leukocytes > 20  
PBMC human peripheral blood mononuclear cells > 50 
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Viable, metabolic active cells could reduce the dye to its insoluble blue-purple 
formazan which can be measured photometrically at 595 nm. In this way, the 
number of viable cells could be quantified. This method is used mainly to 
determine the cytotoxic effects of substances of interest without allowing to 
differentiate between necrotic, apoptotic and antiproliferative effects.  
In the cell lines analysed, the half maximal effective concentrations of MC was 
between 3 to 9 µM (Tab. 1). It is noticeable that especially cancer cells of 
leukaemian origin (HL60, MM6 and Jurkat cells) were most sensitive towards 
MC, with EC50 values of 3 - 4 µM. This led to the decision to concentrate on 
evaluating the effect of MC on leukaemia cells and, in this respect, to test mainly 
HL60, MM6 and Jurkat cells. 
 
 
Fig. 1 Cytotoxicity of MC in HL60 cells, MM6 cells and PBMC. 0.3-0.5 × 106 cells were 
incubated in a microtiter plate with vehicle and increasing amounts of MC for 24 h in the 
appropriate medium. Then, the dye MTT was added to the cells and incubated for another 3 h until 
the untreated control clearly showed blue staining. MTT lysis buffer was added and the plate was 
left shaking 16-20 h overnight at RT. The absorption was measured at 595 nm in a Victor™ plate 
reader. Data are given as mean ± S.E. n=3-5 **p<0.01 
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A strong difference in the potency of MC could be observed between cancer cells 
and primary blood cells where EC50 values were higher than 20 or 50 µM.  
When looking at the concentration-response curve of MC in HL60 cells, MM6 
cells and PBMC the discrepancy of cytotoxicity in non-transformed cells 
compared to leukaemia cells is obvious (Tab. 1, Fig. 1). 
 
12.2 Induction of caspase-cleavage by MC in HL60 cells and 
MM6 cells 
Caspases are cysteinyl-aspartate-specific proteases which exist in the cell as 
inactive uncleaved procaspases and can be cleaved/activated quickly upon 
apoptosis signaling.  Activation of caspases is essential for the programmed cell 
death.  Concerning caspases, one differentiates between the so-called initiator 
caspases and the effector caspases. One of the main substrate of caspase 3 is poly-
ADP-ribose-polymerase (PARP). In non-apoptotic cells, PARP (119 kDa) takes 
part in the DNA-repair. This is not necessary and even undesirable in apoptotic 
cells, therefore PARP is degraded. This degradation can be quantified by the 89 
kDa fragment of PARP which is a classical marker of apoptosis [189].  
The effect of MC on caspase cleavage in HL60 and MM6 cells was elucidated for 
further analysis of apoptosis induction. As control agent for apoptosis induction, 
cycloheximide (CHX), an inhibitor of protein biosynthesis, was used. Q-VD-Oph 
(QVD), a pan-caspase inhibitor, was used to assess if the induction of apoptosis 
by MC is caspase-dependent. 
MC induced cleavage of the initiator caspases 2, 7 and 8 and of effector caspases 
3 and 9 as well as PARP cleavage in a concentration-dependent manner starting at 
concentrations of 3-10 µM (Figs. 2 and 3). Caspase and PARP cleavage by MC 
could be inhibited by the pan caspase inhibitor QVD. CHX induced PARP 
cleavage and cleavage of caspase 8 as expected. 
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Fig. 2 Caspase and PARP cleavage in HL60 cells. 0.2 × 106/ ml HL60 cells were incubated for 
16 h at 37 °C with DMSO, MC, cycloheximide (CHX) or staurosporine (Stauro) respectively. After 
centrifugation, the pellet was lysed with SDS-PAGE sample loading buffer (SDS-b) and analysed 
for caspases and PARP by SDS-PAGE and Western Blot. Data shown are representative for 4-5 
independent experiments. 
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Fig. 3 Caspase and PARP cleavage in MM6 cells. 0.2 × 106/ml MM6 cells were incubated for 16 
h at 37 °C with DMSO, MC, Q-VD-Oph (QVD) or cycloheximide (CHX), respectively. After 
centrifugation, the pellet was lysed with SDS-b and analysed for caspases and PARP by SDS-
PAGE and Western Blot. Data shown are representative for 4-5 independent experiments. 
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Fig. 4 Caspase cleavage and PARP cleavage in PBMC. PBMC were isolated from buffy coats as 
described in the materials and methods section. 0.5 × 106/ml PBMC were incubated for 24 h at 37 
°C with DMSO, MC or daunorubicin (Dauno). After centrifugation, the pellet was lysed with SDS-
b and analysed for caspases and PARP by SDS-PAGE and Western Blot. Data shown are 
representative for 3-4 independent experiments. 
 
 
 
 
 
MC was also tested on PBMC for caspase and PARP cleavage. In these cells, a 
significant effect of MC on PARP, caspase 3 and caspase 9 was evident only at 
concentrations ≥30 µM (Fig. 4). 1 µM daunorubicin induced PARP cleavage as 
well as cleavage of caspase 3 and reduced the amounts of the uncleaved 
procaspase 9 in PBMC. 
Time course experiments for PARP cleavage and caspase 3 and 9 activation by 
MC in HL60 cells, showed that the PARP fragments and active subunits of 
caspases can first be seen after 9 to 12 hours of incubation with MC (Fig. 5B). 
Staurosporine induced PARP cleavage and caspase activation within 3 hours (Fig. 
5C).   
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Fig. 5 Time course of caspase and PARP cleavage in HL60 cells. HL60 cells (0.2 × 106 cells/ml) 
were incubated with (A) 0.2% DMSO, (B) 30 µM MC or (C) 1 µM staurosporine for the indicated 
time periods at 37 °C.  After centrifugation, the pellet was lysed with SDS-b and evaluated for 
caspases and PARP by SDS-PAGE and Western Blot. Data shown are representative for 3 
independent experiments. 
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12.3 DNA fragmentation induced by MC in HL60 cells and 
MM6 cells  
An additional effect which can be observed during apoptosis is DNA 
fragmentation. To evaluate the effect of MC on DNA fragmentation, the DNA 
intercalating fluorophore propidium iodide was used.  
Cells were incubated for 24 h with vehicle, MC or controls. Then, cells were 
harvested, washed once with PBS and carefully resuspended in 100 µl hypotonic 
propidium iodide lysis buffer. After 10 min incubation at RT, the number of 
apoptotic nuclei was measured in a flow cytometer (Fig. 6). 
 
Fig. 6 MC induces DNA fragmentation in HL60 cells and MM6 cells. HL60 cells and MM6 cells 
(0.2 × 106 cells/ml) and PBMC (0.5 × 106 cells/m) were incubated with DMSO,  with 3, 10, 30 and 
60 µM MC or 3 µM staurosporine (PBMC), 1 µM staurosporine (MM6) or 50 µM CHX (HL60) 
for 24 h at 37 °C. Then, cells were harvested, washed in PBS and resuspended in 100 µl hypotonic 
propidium iodide buffer. After 10 min at RT, fluorescence intensities of cell nuclei were measured 
using a flow cytometer (FL2 585/42). Data are given as mean ± S.E. n = 2-5.  *p<0.05, **p<0.01 
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The amount of cells with lower fluorescence intensities (hypodiploid peak, 
subG1) was enhanced with increasing concentrations of MC. A significant effect 
of MC on DNA fragmentation was observed in HL60 cells and MM6 cells at 
concentrations of 10 µM. PBMC were less sensitive to MC and a significant 
although slight effect could be observed only at a concentration of 60 µM MC. 
Staurosporine induced DNA fragmentationin PBMC as well as in MM6 cells (at 3 
µM and 1 µM respectively) and cycloheximide induced DNA fragmentation in 
HL60 cells as expected. 
 
12.4 MC leads to cytochrome c release in HL60 cells and 
MM6 cells 
Caspase cleavage and DNA fragmentation clearly indicated that MC-induced 
cytotoxicity in HL60 cells and MM6 cells is dependent on induction of apoptosis. 
The next step was to evaluate which mechanism is responsible for the effect of 
MC and if the intrinsic, mitochondrial pathway or the extrinsic pathway of 
apoptosis induction is involved. 
 
The initial processes involving the mitochondrial state leading to apoptosis are: a) 
opening of the permeability transition pore (PTP), b) mitochondrial swelling, c) 
loss of mitochondrial membrane potential (∆Ψm), d) building of the mitochondrial 
apoptosis inducing channel (MAC) and e) release of mitochondrial proteins into 
the cytoplasm (cytochrome c, AIF, EndoG). However, the exact order of the 
occurence of each step is still unclear. Since DNA fragmentation might be 
dependent on release of mitochondrial proteins, and also activation of caspase 9 
mainly depends on mitochondrial cytochrome c, the MC-induced release of 
cytochrome c from mitochondria was determined. 
 
Cells were incubated for the times indicated with vehicle, MC or controls. After 
harvesting, the cells were treated with digitonin in order to permeabilise plasma 
membranes by dissolving cholesterol. This way, after centrifugation, the 
supernatant contains proteins of the cytoplasm, whereas mitochondria and other 
organelles remain intact. The release of cytochrome c can therefore be detected in 
the cytoplasm of the cells. 
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MC increased the amounts of cytochrome c in the cytoplasm of MM6 and HL60 
cells after 24h incubation (Fig. 7 and 8). Cycloheximide also induced cytochrome 
c release in MM6 and HL60 cells as expected. The time-course showed that the 
cytochrome c release is induced by MC after 6 to 9 h and that it is not inhibited by 
QVD (Fig. 8). Therefore, MC-induced cytochrome c release is not caspase-
dependent but rather an initial event in apoptosis induction.  
 
Fig. 7 MC induces cytochrome c release in MM6 cells and HL60 cells. 2.5 × 106cells/ml MM6 
cells or HL60 cells were incubated for 24 h in the incubator with vehicle (DMSO), MC or 
cycloheximide (CHX) in the appropriate medium. After centrifugation, cells were treated with 600 
µg/ml digitonin as described in materials and methods. Proteins in the supernatant were 
precipitated with 5% TCA overnight at 4°C. Total amount of protein was determined by Roti-
Nanoquant and equal amounts of protein were loaded onto an SDS-PAGE gel. Data shown are 
representative for 4 independent experiments. 
 
 
Fig. 8 Time course of cytochrome c release induced by MC in HL60 cells. 2.5 × 106 cells/ml 
HL60 cells were incubated for the times indicated with vehicle (DMSO), MC or MC + QVD 
respectively. After centrifugation, cells were treated with 600 µg/ml digitonin as described in 
materials and methods. Supernatant was conducted to protein precipitation with 5% TCA 
overnight at 4°C. Total amount of protein was determined by Roti-Nanoquant and equal amounts 
of protein were loaded onto an SDS-PAGE gel and afterwards analysed by Western Blot. Data 
shown are representative for 2 independent experiments. 
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12.5 MC causes loss of the mitochondrial membrane 
potential ∆Ψm 
The intrinsic induction of apoptosis is characterised by permeabilisation of 
mitochondrial membranes and results in release of cytochrome c. MC is able to 
induce cytochrome c release. How is the induction of cytochrome c release by MC 
mediated? 
Release of cytochrome c is related either to a more or less controlled formation of 
pores such as the PTP and MAC or to mitochondrial swelling and membrane 
disruption. After permeabilisation of mitochondrial membranes, the membrane 
potential ∆Ψm becomes instable which under physiological conditions is 
necessary to drive the ATP-Synthase. Normally the amount of ∆Ψm over the inner 
mitochondrial membrane is around -200 mV [190]. During membrane 
permeabilisation this potential is depleted.  
 
Fig. 9 MC reduces the mitochondrial membrane potential in MM6 cells. MM6 cells (1 × 106/ml) 
were incubated for 24 h with DMSO (veh.) and MC. 1 µM FCCP was added directly to stained 
cells shortly before measuring. After incubation, cells were washed and then stained with 0.75 
µg/ml JC-1 for 15 min at 37 °C. After additional washing in ice-cold PBS, green (FL1) and 
red/orange fluorescence (FL2) were measured in a flow cytometer immediately. Data are given as 
mean ± S.E.  n = 2-5 *p<0.05, **p<0.01 or as representative of 2-5 independent experiments. 
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MM6 cells and PBMC were treated with increasing concentrations of MC and the 
amount of red/green fluorescence was calculated as percentage of ∆Ψm in control 
cells (untreated cells). Carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone 
(FCCP) is a protonophor which can depolarise the plasma and the mitochondrial 
membranes and was used as control.  
Incubation of cells with MC led to a loss of ∆Ψm starting at 3 µM in MM6 cells 
(and HL60 cells, data not shown) but not in PBMC (Fig. 9). A slight but not 
significant effect could be observed in non-transformed mononuclear cells only at 
30 µM. Thus, the selectivity of MC for cancer cells starts at the level of 
mitochondria and involves loss of ∆Ψm. FCCP reduced ∆Ψm in PBMC and MM6 
cells as expected. 
 
12.6 Induction of cytochrome c release and loss of ∆Ψm by 
MC is unaffected by Bcl2 overexpression and 
independent of the opening of the permeability 
transition pore  
MC is able to induce cytochrome c release in HL60 cells and MM6 cells as well 
as loss of ∆Ψm. Next, we determined how these events are triggered and if 
overexpression of the mitochondrial anti-apoptotic Bcl2 decreased apoptosis 
induction by MC. Stable transfectants of Jurkat cells overexpressing Bcl2 and the 
Jurkat mock-transfected (Jvec) cells were used. 
MC reduced the number of viable cells independently of Bcl2 overexpression 
(Fig. 10). The potency of MC in Bcl2-overexpressing cells and Jurkat mock-
transfected cells were similar to the one obtained in the Jurkat control cell line 
(4.01 µM, Tab. 1).  As expected, CHX also led to reduced cell numbers. 
Since reduced cell viability (Fig.10) could be simply due to a decrease in 
mitochondrial metabolism (and therefore decreased reduction of MTT) affected 
by Bcl2 overexpression, apoptosis induction by MC was checked by 
determination of PARP and caspase cleavage (Fig. 11). MC induced a prominent 
PARP and caspase 3 cleavage starting at 10 µM which was independent of the 
overexpression of Bcl2. 1 µM staurosporine also induced cleavage of PARP and 
caspase 3 as expected. 
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Fig. 10 MC reduces cell numbers independently of Bcl2 overexpression. 3 × 105 cells were 
incubated in a microtiter plate with vehicle, MC or 50 µM cycloheximide (CHX) for 24 h. Then, 
the dye MTT was added to the cells and incubated for another 3 h until the untreated control  
clearly showed blue staining. MTT lysis buffer was added and the plate was left shaking 16-20 h 
overnight at RT. The absorption was measured at 595 nm in a Victor™ plate reader. Data are 
given as mean ± S.E. n=3-5 *p<0.05, **p<0.01 
 
 
 
Fig. 11 Caspase and PARP cleavage in Bcl2-overexpressing Jurkat cells. 0.2 × 106/ ml Jurkat 
cells overexpressing Bcl2 were incubated for 16 h at 37 °C with DMSO, MC or staurosporine 
(Stauro) respectively. After centrifugation, the pellet was lysed with SDS-b and analysed for 
caspases and PARP by SDS-PAGE and Western Blot. Data shown are representative for 3 
independent experiments. 
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The loss of mitochondrial membrane potential ∆Ψm was significantly induced by 
MC in both cell types (Fig. 12). Also, MC-induced cytochrome c release in Bcl2-
overexpressing Jurkat cells as well as in the mock-transfected Jurkat cells could 
be observed starting at 3 µM MC (Fig. 13). Interestingly, the chelerythrine-
induced cytochrome c release, which is dependent on PTP and thus partly on Bcl2 
proteins, is diminished in Bcl2-overexpressing Jurkat cells compared to the mock-
transfected Jurkat cells (Fig. 13). Since Bcl2 overexpression did not abolish the 
effects of MC, it is reasonable to speculate that Bcl2 proteins are not involved in 
the induction of apoptosis by MC. 
 
 
Fig. 12 MC reduces the mitochondrial membrane potential in Bcl2-overexpressing Jurkat cells. 
Jurkat cells overexpressing Bcl2 (Bcl2 overexpr) or MOCK-transfected cells (Jvec) were adjusted 
to 1× 106 /ml and incubated for 24 h with vehicle and MC. 3 µM FCCP was added directly to 
stained cells shortly before measuring. After incubation, cells were washed and then stained with 
0.75 µg/ml JC-1 for 15 min at 37 °C. After additional washing in ice-cold PBS, green (FL1) and 
red/orange fluorescence (FL2) were measured in a flow cytometer immediately. Data are given as 
mean ± S.E.  n = 3-4 *p<0.05, **p<0.01 or are representative for 3-4 independent experiments. 
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Fig. 13 MC induces cytochrome c release in Bcl2-overexpressing Jurkat cells. 2.5 × 106/ml 
Bcl2-overexpressing Jurkat cells (Jurkat Bcl2) or the MOCK-transfected Jurkat cells (Jvec) were 
incubated for 24 h at 37 °C with vehicle, MC or chelerythrine (Chel) in the appropriate medium. 
After centrifugation, cells were treated with 300 µg/ml digitonin as described in materials and 
methods. The supernatant was used for protein precipitation with 5% TCA overnight at 4°C. The 
total amount of protein was determined by Roti-Nanoquant and equal amounts of protein were 
loaded onto an SDS-PAGE gel and afterwards analysed by Western Blot. Data shown are 
representative for 3 independent experiments. 
 
To evaluate if the apoptosis induction by MC involves the PTP we used 
chelerythrine in combination with cyclosporin A (CsA). Chelerythrine was shown 
to be a potent PKC inhibitor [191] and leads to opening of the PTP by directly 
targeting mitochondria [192]. CsA is a substance isolated from the fungus 
Tolypocladium inflatum GAMS. It can block the opening of the PTP by binding to 
cyclophilin D which is also a part of the pore complex [193]. 
We tested the cytotoxic effect of chelerythrine in MM6 cells and PBMC and we 
analysed if it is possible to abolish the effect by CsA. Then, MC in combination 
with CsA was given to the cells and the effects were compared to the ones 
obtained by using chelerythrine (Fig. 14). 
Again, MC reduced the number of viable MM6 cells starting from 3 µM and 
showed the first significant effect in PBMC only at 30 µM MC. At 10 µM, 
chelerythrine is cytotoxic for MM6 cells and PBMC reducing cell numbers to 10 - 
20% of vehicle-treated cells. When adding 1 µM CsA together with chelerythrine, 
cytotoxicity could be reduced with high significance in MM6 cells and PBMC. 
When giving the same amount of CsA to cells treated with 10 µM MC, the effect 
of MC could not be reversed. From these results we can deduce that MC still 
shows cytotoxic effects although the opening of the PTP is blocked by CsA. Thus 
MC induces cytochrome c release and subsequently causes caspase 9 and caspase 
3 activation independent of the PTP.      
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Fig. 14 The effect of MC on cell viability is not reversed by the PTP inhibitor cyclosporine A. 
3 × 105 MM6 cells or 5 × 105 PBMC were incubated in a microtiter plate for 24 h with vehicle 
(DMSO), MC and/or 10 µM chelerythrine (Chel) and/or 1 µM cyclosporine A (CsA). Then, MTT 
was added to the cells and incubated for another 3 h until the untreated control clearly showed 
blue staining. MTT lysis buffer was added and the plate was left shaking 16-20 h overnight at RT. 
The absorption was measured at 595 nm in a Victor™ plate reader. Data are given as mean ± S.E. 
n=2-3 *p<0.05, **p<0.01, ***p<0.001 (one-way ANOVA, Bonferroni post-hoc). 
 
12.7 Caspase 9 is essential for apoptosis induction by MC 
Induction of cytochrome c release and loss of ∆Ψm after MC incubation indicates 
that the intrinsic pathway of apoptosis induction is involved. To examine whether 
the effects of MC on cell viability are also due to activation of the extrinsic way of 
apoptosis induction, we examined if death receptors, the Fas-associated death 
domain (FADD) or caspase 8 are essential mediators of the effect of MC. As 
previously shown [45], MC could potently decrease cell viability (MTT assay) of 
the neuroblastoma cell line UKF-NB-3 which are resistant to typical death 
receptor stimuli [183, 194]. After addition of the death receptor ligands TNFα, Fas 
or TRAIL, no effect on cell viability could be observed in UKF-NB-3 although 
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they caused cell death at the same concentrations in Jurkat cells. This indicates 
that MC acts not likewise to classical death receptor stimuli. 
Interestingly, MC caused cell death (trypan blue staining) and PARP cleavage in 
Jurkat cells deficient in FADD, and in the Jurkat cell line DD3, which is deficient 
in CD95-mediated signalling [195]. This indicates that the Fas-receptor and the 
associated FADD are not necessary for the effect of MC on cell viability and 
apoptosis (Fig. 15). In addition, Jurkat cells lacking caspase-8 which is the 
caspase downstream of the Fas receptor were susceptible to MC.  
 
Fig. 15 PARP cleavage and cell numbers in different Jurkat cells incubated with MC (Data 
from Jurkat CD95-defective obtained by I. Tretiakova, Frankfurt).  Normal Jurkat cells or 
Jurkat cell lines deficient in either FADD, CD95 signalling (CD95-defective), caspase 8, caspase 
9 or caspase 9 and then retransfected with caspase 9 were incubated with 3, 10, and 30 µM MC, 
vehicle (DMSO) or 50 µM cycloheximide (CHX). Cells were harvested after 48 h and cell viability 
was determined by trypan blue staining. In the absence of test compound (vehicle-treated), the 
numbers of viable cells for each cell line increased within 48 h from 0.2 × 106/ml to 0.70 × 106/ml  
for normal Jurkat cells, 0.89 × 106/ml for CD95-defective, 0.92 × 106/ml  for FADD-/-, 0.58× 
106/ml  for casp 8-/-, 0.49 × 106/ml for casp 9-/-, and 0.81 × 106/ml for casp 9-/- retransfected, 
respectively. For analysis of PARP cleavage, cells were harvested after 16 h, total cell lysates 
were prepared and analysed for processing of PARP (89 kDa) using SDS-PAGE and Western 
Blot. Results are representative for at least 3 independent experiments. ± S.E. *p<0.05, **p<0.01 
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Interestingly, Jurkat cells deficient in caspase 9 were partially resistant to the 
effects of MC on cell viability, and PARP cleavage was not apparent. Re-
transfection of caspase 9-/- cells with caspase 9 recovered the ability of MC to 
reduce cell viability and induce PARP cleavage. It should be noted that the 
reduced numbers of caspase 9-/- Jurkat cells by MC (Fig. 15) is not due to reduced 
cell viability, confirmed by analysis of DNA fragmentation (Fig. 16). In caspase-
9-/- Jurkat cells treated with 30 µM MC, no increase in the numbers of apoptotic 
nuclei was detectable, while in caspase 9-retransfected cells MC caused a clear 
leakage of fragmented DNA (Fig. 16). In Jurkat cells deficient in caspase 9 there 
was no cleavage of caspase 8 by MC detectable, while the Fas receptor ligand 
could still induce caspase 8 cleavage (Fig. 17) indicating a central and initial role 
of caspase 9 in apoptosis induction by MC. 
 
 
Fig. 16 MC does not induce DNA fragmentation in Jurkat which are caspase 9-deficient. 
Caspase 9-deficient Jurkat cells (Casp 9 neg) and caspase 9-deficient Jurkat cells again 
retransfected with caspase 9 (Casp 9 retr) (0.2 × 106/ml) were incubated with DMSO, 3, 10 and 
30 µM MC, 1 µM staurosporine (Stauro) and 100 ng/ml FAS ligand (FASL) for 24 h at 37 °C. 
Then, cells were harvested, washed in PBS and resuspended in 100 µl hypotonic propidium iodide 
buffer. After 10 min at RT, fluorescence intensities of cell nuclei were measured using a flow 
cytometer (FL2 585/42). Data are given as mean ± S.E. n = 3-6.  *p<0.05, **p<0.01 
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Fig. 17 MC does not lead to caspase 8 cleavage in caspase 9-deficient Jurkat cells.  Jurkat cells 
deficient in caspase 9 were treated with the indicated compounds for 16 h and were then analysed 
for cleavage of caspase 8 by SDS-PAGE and Western Blot. Similar results were obtained in two 
additional experiments. 
 
 
Fig. 18 MC reduces the mitochondrial membrane potential in caspase 9-deficient Jurkat cells. 
Jurkat cells deficient in caspase 9 (Casp9 neg) or deficient in caspase 9 and retransfected (Casp9 
retr) with caspase 9 were adjusted to 1 × 106 /ml and incubated for 24 h with DMSO (veh.), MC or 
1 µM staurosporine (Stauro). After incubation, cells were washed and then stained with 0.75 
µg/ml JC-1 for 15 min at 37 °C. After additional washing in ice-cold PBS, green (FL1) and 
red/orange  fluorescence (FL2) were measured in a flow cytometer immediately. Data are given as 
mean ± S.E.  n = 1-3 or are representative for 1-3 independent experiments (staurosporine and 
caspase 9-retransfected Jurkat cells: n = 1). **p<0.01 
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As seen in Fig. 18, MC still induced loss of ∆Ψm in caspase 9-deficient cells 
comparable to caspase 9-retransfected Jurkat cells. In conclusion, the inability of 
MC to induce apoptosis in caspase 9-deficient cells is due to the lack of caspase 9 
activity and not due to impairment of distal events, leading to caspase 9 
activation.  
 
12.8 MC induces G2 phase arrest in caspase 9-deficient 
Jurkat cells 
In caspase 9-deficient Jurkat cells, the effect of MC on PARP cleavage could be 
abolished. Nevertheless, MC could still partially reduce cell numbers although not 
as prominent as in Jurkat wt or in caspase 9-retransfected cells. We checked on 
two possible reasons for this decrease in cell numbers. First, we tested if MC 
causes necrosis in caspase 9-deficient Jurkat cells and second we tested whether 
MC blocks cell proliferation. 
One event during early apoptosis is the externalization of the phospholipid 
phosphatidylserine (PS). Under normal conditions, PS is located to the inner layer 
of the plasma membrane. Upon apoptosis stimulation it is flipped to the outer 
membrane and functions as signal for macrophages to bind and ingest the 
apoptotic cell. To evaluate whether reduction of cell viability by MC in caspase 9-
deficient Jurkat cells is due to apoptotic or necrotic events, we analysed PS 
externalisation by Annexin V/ PI assay (Fig. 19). 
After 16 hours exposure, MC and staurosporine both led to an increase of 
Annexin V-positive (= apoptotic) cells when caspase 9 is retransfected. In cells 
deficient in caspase 9, no effect could be seen (same effects after 6 or 20 hours 
respectively, data not shown). This excludes that MC causes necrosis in caspase 
9-deficient Jurkat cells.  
In caspase 9-retransfected Jurkat cells the amounts of double positive PI- and 
AnnexinV stained cells was quite high. Since in in vitro cell culture apoptotic 
cells are not phagocytised by cells of the immune system, apoptotic cells become 
secondary necrotic or late apoptotic. Here, similar to necrosis, cell membranes 
disintegrate and become permeable for PI, thus giving a positive signal for 
necrosis. In this respect, necrotic and secondary necrotic cells can not be separated 
by this method. Since in caspase 9-deficient Jurkat cells MC did not lead to 
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increased amounts of cells with Annexin V or propidium iodide staining at all, 
necrosis induction could be definitely excluded. 
 
Fig. 19 MC does not induce necrosis in caspase 9-deficient cells. Cells (0.5 × 106/ml) were 
incubated with vehicle (DMSO), 30 µM MC or 1 µM staurosporine (Stauro) for 16 h at 37 °C. 
Then, 0.25× 106 cells were harvested, washed in ice-cold PBS and resuspended in 1 x annexin V 
binding buffer (Vybrant Apoptosis Kit #2, Molecular probes). After adding Alexa Fluor 488-
Annexin V and PI, cells were analysed with a flow cytometer (FL1 vs. FL2) to give the amounts of 
viable, apoptotic and secondary (sec.) necrotic cells. Data are given as representatives (upper 
part) or given as mean ± S.E. n = 3.  *p<0.05, **p<0.01 
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Second, we looked at the cell cycle distribution of caspase 9-deficient and caspase 
9-retransfected Jurkat cells (Fig. 20). Cells were incubated for 24 hours with 
DMSO, MC or staurosporine (which is known to be a strong G2-phase arrestor).  
 
 
 
 
Fig. 20 MC induces cell cycle arrest in caspase 9-deficient Jurkat cells. Jurkat cells deficient in 
caspase 9 (Casp 9 neg) or deficient in caspase 9 and again retransfected with caspase 9 (Casp 9 
retr)(0.2 × 106/ml) were incubated overnight at 37 °C for 24 h with vehicle (DMSO), 3, 10 or 30 
µM MC or 1 µM staurosporine (Stauro),  respectively. Then, 30,000 cells were harvested, washed 
in PBS and carefully resuspended in hypotonic propidium iodide buffer. After 10 min incubation at 
RT, the fluorescence intensities of the cell nuclei were measured using a flow cytometer (FL3 vs. 
counts). Data are given as mean from 4-7 independent experiments. ±S.E. *p<0.05, **p<0.01 
 
 
MC led to a G2 phase cell cycle arrest in caspase 9-deficient Jurkat cells (Fig. 20, 
Casp 9 neg). Also, caspase 9-retransfected (Fig. 20) and Bcl2-overexpressing 
Jurkat cells (data not shown) were arrested in G2-phase. Since apoptotic events 
decreased total cell numbers and led to a prominent shift of the main host of the 
cells into subG1 phase, in caspase 9-retransfected Jurkat cells the cell cycle arrest 
was not as prominent as compared to caspase 9-deficient cells. Staurosporine led 
to an increase of cells in G2 phase after 24 hours as expected.  
Although MC was not able to induce apoptosis in caspase 9-deficient Jurkat cells, 
the inhibition of the cell cycle at the G2 phase led to the decrease in numbers of 
viable cells (as observed in Fig. 15) 
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13 The effect of MC on signal transduction 
pathways in PMNL  
Based on the results reported in the first part of this thesis, MC acts via the 
intrinsic pathway of apoptosis induction leading to loss of mitochondrial 
membrane potential and cytochrome c release and triggering caspase 9 activation. 
In caspase 9-deficient cells, no apoptosis could be induced by MC. 
Next, we focussed on immediate events induced by MC. What are the early 
mechanisms for the effects that finally lead to apoptosis? Recent work about short 
term effects of MC by Dr. C. Feißt and colleagues showed that in PMNL MC 
inhibits fMLP-induced ROS production, leukocyte elastase release and Ca2+ 
mobilisation from intracellular stores [18]. These events are closely related to the 
mechanism of (especially) G protein coupled receptor (GPCR) signaling. In order 
to identify the initial pathways affected by MC the following chapters will 
elucidate the influence of MC on cellular signaling pathways in PMNL and in 
HL60 cells.  
13.1 MC suppresses fMLP-induced phosphorylation of MAP 
Kinases and Akt/PKB.  
fMLP (N-formyl-methionyl leucyl-phenylalanine) is a small peptide derived from 
bacteria and acts as chemoattractant for polymorphonuclear leukocytes (PMNL) 
resulting in the release of proteases such as cathepsin G or leukocyte elastase. 
fMLP acts via the GPCR formyl peptide receptor (FPR) leading to activation of 
MAP Kinases, intracellular Ca2+ release and ROS formation [196, 197]. It was 
shown previously that MC inhibits fMLP- and ionomycine-induced peroxide 
(ROS) formation in PMNL (IC50= 0.8 µM) and could inhibit fMLP-evoked Ca2+ 
release from intracellular stores (IC50= 0.55 µM) [18]. 
Here, we evaluated activation of MAPK after incubation of freshly isolated 
human PMNL with vehicle (DMSO), MC and staurosporine and stimulation with 
fMLP (Fig. 21). 
The fMLP-induced phosphorylation of ERK, p38 MAPK, JNK and Akt/PKB was 
abolished when cells were incubated with MC starting at a concentration of 3 µM. 
In contrast, the direct PKC substrate MARCKS was unaffected by MC (Fig. 21). 1 
µM staurosporine did not affect ERK, JNK and p38 MAPK phosphorylation, had 
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only a slight effect on Akt/PKB phosphorylation but strongly decreased 
MARCKS phosphorylation. 
 
 
Fig. 21 MC reduces phosphorylation of ERK, JNK/SAPK and p38 MAPK as well as Akt/PKB in 
fMLP-stimulated PMNL. PMNL freshly isolated from the blood of healthy donors (108/ml) were 
resuspended  in PBS + 0.1% glucose and 1 mM CaCl2 (PGC). Cells were incubated for 30 min at 
37 °C with DMSO, MC or staurosporine (Stauro) before stimulation with 100 nM fMLP for 1.5 
min. Samples were loaded to an SDS-PAGE gel and amounts of proteins were quantified by 
Western Blot. Data are given as representative for 3 independent experiments. 
 
13.2 MC affects signaling of different GPCRs leading to 
decreased phosphorylation of MAPkinases and 
Akt/PKB. 
Leukotriene B4 (LTB4) is a potent chemoattractant produced in leukocytes upon 
stimulation with inflammatory mediators. LTB4 activates leukocytes and 
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neutrophils and in the latter type induces ROS formation and release of proteases 
[198, 199]. Signal transduction is primarily induced by binding of LTB4 to its 
high-affinity receptor BLT1 which is also a GPCR.   
To evaluate whether MC also affects signaling of other GPCRs than FPR, we 
checked the phosphorylation of Akt and ERK after stimulation of PMNL with 
LTB4. Similar to the results in fMLP-stimulated PMNL, MC significantly reduced 
phosphorylation of ERK 1/2 without affecting the total amount of ERK. 
Phosphorylation of Akt/PKB was also slightly reduced (Fig. 22A). Staurosporine 
failed to reduce ERK phosphorylation but strongly decreased amounts of 
phospho-Akt/PKB as expected. We also checked the effect of MC on AA and 5-
HETE signaling and similar results were obtained for MC (Fig. 22B and C). The 
5-LO inhibitor BWA4C could decrease AA-induced ERK 1/2 phosphorylation but 
failed to decrease 5-HETE-induced ERK phosphorylation (Fig. 22B and C). This 
indicates that activation of the MAPK by AA is dependent on the conversion of 
AA by 5-LO. 
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Fig. 22 MC reduces phosphorylation of ERK and Akt/PKB in LTB4-, AA- and 5-HETE- 
stimulated PMNL. PMNL freshly isolated from the blood of healthy donors (108/ml) were 
incubated in PGC for 30 min at 37 °C with DMSO, MC and staurosporine (Stauro) before  
stimulation with 500 nM LTB4  for 1 min (A), 1µM arachadionic acid (AA) for 1.5 min (B) or 100 
ng/ml 5-HETE for 1 min (C). Samples were loaded to an SDS-PAGE gel and amounts of proteins 
were quantified using specific antibodies. Data shown are representative for 2-4 independent 
experiments. 
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13.3 MC leads to a slight decrease in PTPase activity in 
PMNL. 
So far, we could show that MC interferes with GPCR signaling leading to 
reduction of kinase phosphorylation/activation. Several reports described that 
GPCR-dependent activation of the Ras/Raf/MEK/ERK pathway involves cross 
talk to receptor tyrosine kinases (RTKs) [173, 174, 158, 200, 201]. Aside from 
protein kinases, protein tyrosine phosphatases (PTPases) have also an influence 
on MAP Kinase signaling by removing the phosphate from tyrosine residues of 
phosphorylated kinases such as Src-homology 2 containing (Shc), growth factor 
receptor bound protein 2 (Grb2), son of sevenless (Sos) and sarcoma (Src) family  
kinases. Sos is a guanine nucleotide exchange factor signaling from receptor 
tyrosine kinases to the small G protein Ras. We assumed that MC has an 
inhibitory influence on tyrosine kinases. This influence can derive from direct 
inhibition of the signaling cascade of tyrosine kinases directly or from activation 
of  PTPases.  
 
To elucidate if MC has an effect on tyrosine kinases (and therefore on 
phosphorylation of tyrosine residues) and an effect on the activity of PTPases, we 
tested PTPase activity in PMNL and assessed phosphorylation of tyrosine 
residues. 
 
Suprisingly, MC rather reduced PTPase activity in PMNL (Fig. 23A) in a time 
dependent manner (Fig. 23B). Also an increase of tyrosine phosphorylation was 
observed in fMLP-stimulated PMNL pre-treated with MC, suggesting that MC 
does not reduce the activity of tyrosine kinases (Fig. 23C). Correspondingly, in 
unstimulated PMNL, MC led to an increase of phosphorylation of tyrosine 
residues (data not shown). Staurosporine inhibited the phosphorylation of tyrosine 
residues as expected (Fig. 23C). PAO, an inhibitor of PTPases, reduced PTPase 
activity and accordingly increased the phosphorylation of tyrosine residues (Fig. 
23C) as expected. 
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Fig. 23 MC reduces PTPase activity in PMNL which leads to increased phosphorylation of 
tyrosine-residues. PMNL were freshly isolated from the blood of healthy donors. A) PTPase 
activity. Cells (8 × 105) were incubated in PGC for 30 min at 4 °C with DMSO, MC or 20 µM of 
the PTPase inhibitor phenylarsine oxide (PAO). After lysing the cells and centrifugation of the 
lysates, p-nitrophenyl phosphate (pNPP) was added to the supernatants and absorption at 405 nm 
was measured in a Victor™ plate reader. n = 3 ± S.E.  *p<0.05, **p<0.01 B) Time course of 
PTPase activity. Cells (8 × 105) were incubated for the times indicated at 4 °C and then treated 
with DMSO, 10 µM MC or 20 µM PAO as described under A). Data are representative for 2 
independent experiments. C) Increase in phosphorylation of tyrosine residues. 1 × 107 cells were 
incubated for 30 min at 37 °C with DMSO, MC, staurosporine (Stauro) or PAO before stimulation 
with 100 nM fMLP for 1.5  min. Incubation was stopped by adding SDS-b and putting the samples 
on ice. Data are representative for 3 independent experiments. 
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13.4 The effect of MC on MAP Kinase signaling is not due to 
a direct effect on PKC. 
Next, we concentrated on the classical signaling cascade from the fMLP-induced 
FPR1 receptor pathway involving G proteins, phospholipase C beta (PLCβ) and 
protein kinase C (PKC). Activation of PKC depends on binding of phorbol esters 
such as DAG or on binding of Ca2+ respectively. PKC is able to activate Ras and 
c-Raf directly, though the exact mechanism is still unclear [175, 158]. 
To elucidate if PKC is directly affected by MC, freshly isolated PMNL were 
treated with DMSO, MC and staurosporine, stimulated with 100 nM PMA for 3 
min (Fig. 24A) and phosphorylation of the direct PKC substrate MARCKS and of 
ERK was assessed. PMA, a phorbol ester, is able to enter the cells and target PKC 
directly, stimulating it and thus substitutes for DAG.  
MC strongly decreased ERK phosphorylation starting from the concentration of 3 
µM also after PMA stimulation. MARCKS phosphorylation was not affected by 
MC in fMLP-stimulated PMNL (Fig. 21) and also not in PMA-stimulated cells 
(Fig. 24A). Staurosporine, a kinase inhibitor, could decrease PMA-induced 
MARCKS and ERK phosphorylation as expected (Fig. 24 A). 
To determine if the depletion of Ca2+ from intracellular stores by MC affects PKC 
activity, we added ionomycin combined with PMA to cause influx of Ca2+ from 
the extracellular medium.  
Ionomycin led to a further increase in MARCKS and ERK phosphorylation. 
Nonetheless MC was still able to decrease the amount of ERK phosphorylation 
but had no obvious effect on MARCKS phosphorylation (Fig. 24B). As expected, 
staurosporine strongly decreased MARCKS phosphorylation and had only a slight 
effect on ERK phosphorylation. 
Interestingly, MC had no direct inhibitory effect on PKC directly. In contrast, MC 
rather increased phosphorylation of the PKC substrate MARCKS (Fig. 21) in 
absence of PMA. Nonetheless, ERK phosphorylation is decreased. This narrows 
the number of possible targets for MC to the proteins located downstream of PKC 
and upstream of ERK which are e.g. Ras, Raf and MEK or alternative activation 
involving cross talk with other pathways (e.g. MEKK1).  
Despite a complete suppression of fMLP-induced ERK phosphorylation by 10 - 
30 µM MC, no complete inhibition was observed, when PMA was used as 
stimulus (compare Fig. 21 to Fig. 24). This might suggest that MC does not 
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completely abolish the PKC signal leading to ERK phosphorylation but could 
affect only selected pathways. 
 
 
 
 
Fig. 24 MC reduces ERK phosphorylation induced by PMA stimulation without affecting PKC 
directly. PMNL freshly isolated from the blood of healthy donors were set to 108 /ml in PGC. A) 
ERK and MARCKS phosphorylation. Cells were incubated for 30 min at 4 °C with DMSO, MC 
or staurosporine (Stauro). Then, cells were stimulated with 100 nM PMA for 3 min,  incubation 
was stopped by adding ice-cold SDS-b and samples were analysed for phospho-ERK and phospho-
MARCKS. Data are representative for 3 independent experiments. B) ERK and MARCKS 
phosphorylation with PMA and ionomycin. Cells were incubated as before and then stimulated 
with 100 nM PMA for 3 min and 1 µM ionomycin for 2 min. Data are representative for 3 
independent experiments. 
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13.5 Time dependency of decreased phosphorylation of 
ERK and MEK by MC in PMA-stimulated PMNL  
Usually after activation of kinases, they become inactivated again after some time 
due to dephosphorylation events. To elucidate if MC shows a graduated effect on 
MARCKS phosphorylation compared to DMSO-treated cells and to see how MC 
affects phosphorylation states of MEK and ERK over the time, PMNL were 
stimulated with PMA for different times (0 to 30 min) and phosphorylation of 
kinases was detected by Western Blot (Fig. 25). 
 
Fig. 25 Time dependency of inhibition of ERK and MEK phosphorylation by MC. PMNL 
(108/ml) freshly isolated from the blood of healthy donors were incubated in PGC  for 30 min at 37 
°C with 0.2% DMSO or 10 µM MC before stimulation with 100 nM PMA  for the times indicated. 
Samples were loaded to an SDS-PAGE gel and amounts of phosphorylated proteins were 
quantified using specific antibodies. Data are representatives of 2 independent experiments.  
 
 
MC significantly reduced MEK and ERK phosphorylation in PMA-stimulated 
PMNL, but rather increased MARCKS phosphorylation compared to DMSO-
treated cells. Interestingly, the activation of ERK and MEK was not totally 
inhibited. Phosphorylation of MEK and ERK is rather delayed in MC-treated cells 
compared to DMSO-treated cells and decrease in phosphorylation started earlier 
when cells were incubated with MC. No difference in the time to reach the onset 
of MARCKS phosphorylation between MC- and DMSO-treated cells could be 
observed.  
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13.6 MC reduces the amount of active GTP-bound Ras in 
fMLP or PMA-stimulated PMNL. 
Ras is a small G protein with GTPase activity which is activated by the exchange 
of guanosine diphosphate with guanosine triphosphate. When Ras activates c-Raf, 
the subsequent protein of the cascade, c-Raf is recruited to the membrane and is 
able to transmit the signal by phosphorylation to MEK. Using a prenyl-residue, 
Ras is anchored to the inner side of the plasma membrane bringing it in close 
proximity to associated receptors and effector proteins.  
Freshly isolated PMNL were treated with DMSO, MC and staurosporine. Cells 
were then stimulated with 100 nM fMLP for 1.5 min or with 100 nM PMA for 3 
min and the amount of active Ras was analysed. In fMLP- and PMA-stimulated 
cells, MC significantly reduced the amount of the GTP-bound active form of Ras 
starting at concentrations of 0.3 to 1 µM (Fig. 26). While in fMLP-stimulated 
cells MC might inhibit Ras activation by a pathway not involving PKC (Fig. 
Pathways of ERK activation by fMLP and PMA), in PMA-stimulated PMNL, MC 
must target downstream of PKC in order to decrease Ras activation.  
Staurosporine reduced the amount of GTP-bound Ras in PMA- and fMLP-
stimulated cells as expected. 
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Fig. 26 MC reduces the amount of GTP-Ras in PMA and fMLP-stimulated PMNL.  PMNL 
(108/ml) freshly isolated from the blood of healthy donors were incubated for 30 min at 37 °C with 
DMSO, MC or staurosporine (Stauro) before stimulation with 100 nM fMLP for 1.5 min (A) or 
100 nM PMA for 3 min (B). After stopping the reaction, cells were lysed and lysates were 
transferred onto Raf-Ras binding domain (Raf-RBD) coupled Sepharose beads. 5 µl of lysates 
were directly subjected to SDS-PAGE and Western blot for detection of total amounts of Ras. Ras-
GTP bound to the Sepharose beads was extracted from the lysates by centrifugation, several 
washing steps and addition of SDS-b. Samples were then loaded to an SDS-PAGE gel and 
amounts of Ras-GTP were quantified by Western Blot using a Ras-specific antibody. Data are 
representative for 3 independent experiments.  
 
 
DMSO 0.2 0.2 - - - - - [%]
MC - - 0.3 1 3 10 - [µM]
fMLP - + + + + + + 100 nM
Ras-GTP
total Ras
DMSO 0.2 0.2 - - - - - [%]
MC - - 0.3 1 3 10 - [µM]
Stauro - - - - - - 1 [µM]
PMA - + + + + + + 100 nM
Ras-GTP
total Ras
Stauro - - - - - - 1 [µM]
A
B
 Results    99 
 
13.7 Phosphorylation of c-Raf (Raf 1) in PMA and fMLP-
stimulated PMNL is diminished by MC. 
Downstream of the G protein Ras the protein kinase c-Raf (also termed Raf1) is 
located. Activation of c-Raf or signal transduction from Ras downstream to c-Raf, 
MEK and ERK is supposed to be accomplished by the formation of a complex of 
Ras, c-Raf, MEK and the two scaffolding proteins kinase supressor of Ras (KSR) 
and connector enhancer of KSR (CNK). 
PKC, apart from activating Ras directly, is able to activate c-Raf and MEK. Since 
MC decreased the amount of active GTP-Ras in PMA-stimulated PMNL we tried 
to analyse the effect of MC on c-Raf phosphorylation in PMA-stimulated cells. 
We observed a decrease in MEK phosphorylation after incubation with MC, 
according to the decrease in ERK phosphorylation in PMA- or fMLP-treated cells 
(Fig. 27). Regarding the phosphorylation state of the c-Raf isoform, we could see 
a decrease in phosphorylation of the Ser338 in fMLP- and PMA-stimulated cells 
which is thought to be phosphorylated by Ras and to lead to the activation of c-
Raf. On the other hand, phosphorylations of the serine residues 289, 296 and 301, 
that are targeted by Src kinases, were not reduced but rather slightly stimulated by 
MC (data not shown), which is in accordance to the data concerning the slight 
increase in phosphorylation of tyrosine residues (see Fig. 23A and C). MC did not 
have an effect on phosphorylation of the similar site in B-Raf (Ser445) (Fig. 28).  
Staurosporine reduced the phosphorylation of c-Raf induced by fMLP or PMA as 
expected and reduced MEK phosphorylation in PMA-stimulated cells. 
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Fig. 27 MC reduces phosphorylation of c-Raf and MEK 1/2 in fMLP- and PMA-stimulated 
PMNL. PMNL (108/ml) freshly isolated from the blood of healthy donors  were incubated in PGC 
for 30 min at 37 °C with DMSO, MC or staurosporine (Stauro) before  stimulation with 100 nM 
fMLP for 1.5 min or 100 nM PMA  for 3 min. Samples were loaded to an SDS-PAGE gel and 
amounts of proteins were quantified by Western Blot using phospho-c-Raf (Ser338) and phospho-
MEK 1/2 specific antibodies. Data are representative for 3 independent experiments.  
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Fig. 28 Phosphorylation of B-Raf in fMLP and PMA-stimulated PMNL is unaffected by MC. 
PMNL freshly isolated from the blood of healthy donors were set to 108/ml. Cells were incubated 
in PGC for 30 min at 37 °C with DMSO, MC or staurosporine (Stauro) before stimulation with 
100 nM fMLP for 1.5 min or PMA for 3 min. Incubation was stopped by adding SDS-b and putting 
the samples on ice. After cooking and sonification, samples were loaded to an SDS-PAGE gel and 
amounts of proteins were measured using phospho-B-Raf (Ser445) specific antibody.  Data are 
representative for 3 independent experiments.  
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14 Effects of MC on signal transduction in HL60 
cells 
 
In PMNL MC strongly inhibited phosphorylation of MAPK and several other 
targets (chapter 2) which probably are the mechanisms leading to the effects 
observed by others [18] including ROS-production, leukocyte elastase release and 
Ca2+ mobilisation. Next, we analysed whether MC has the same effects in the 
acute myeloid leukaemia HL60 cells. One feature of HL60 cells is upregulation of 
N-Ras activity and of the whole downstream cascade towards ERK. We aimed to 
evaluate whether pro-apoptotic effects of MC are induced by targeting MAPK 
signaling in HL60 cells and whether this is the possible point of discrimination 
between non-transformed cells and degenerated cancer cells. 
The ERK pathway has an important role in regulating differentiation and cell 
growth and several downstream transcription factors have been identified. The 90 
kDa ribosomal S6 kinases p90RSK and Elk-1 are two examples. One is a key 
regulator of glucose homeostasis and cell size [202] the other, when 
overactivated, plays a role in intestinal cells after infection with Helicobacter 
pylori. Other MAPK pathways such as p38 MAPK or JNK are responsible for 
apoptosis and proliferation control.  
Here we tested if MC is able to interfere with signaling pathways similarly to the 
effects in PMNL, irrespective of the upregulation of MAPK pathways in HL60 
cells. 
 
14.1 The long term effect of MC on ERK phosphorylation in 
HL60 cells is caspase-dependent 
Along with the studies regarding the apoptosis inducing effect of MC, it was first 
tested if MC has long term effects (16 h) on ERK phosphorylation. ERK 
inhibition may in fact result in a reduction of BAD (inhibitory) phosphorylation 
which would enable it to translocate to the mitochondrial membrane and inhibit 
antiapoptotic Bcl2 proteins. 
HL60 cells were incubated for 16 h with vehicle, MC, staurosporine and/or the 
pan caspase inhibitor QVD, and the amounts of cleaved PARP, phospho-
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MARCKS, phospho-ERK 1/2, ERK 1/2 and beta-actin were quantified by SDS-
PAGE (Fig. 29). 
MC induced PARP cleavage as before indicating apoptosis induction. When 
caspases were inhibited by QVD, PARP cleavage by MC was abolished.  
The phosphorylation of MARCKS and of ERK was clearly diminished when 
incubating the cells with MC or staurosporine. Adding QVD together with MC 
reversed the effect of MC, indicating that the decrease in ERK phosphorylation by 
MC is caspase-dependent.  
Taken together with the fact that MC induces apoptosis independently of Bcl2 
overexpression, as was shown above, it is highly unlikely that downregulation of 
ERK and therefore BAD phosphorylation is the reason for induction of the 
mitochondrial pathway of apoptosis.  
 
 
 
Fig. 29 The decrease in ERK and MARCKS phosphorylation in HL60 cells after 16 h 
incubation with MC is caspase-dependent. HL60 (0.2 × 106 /ml in the appropriate medium) were 
incubated for 16 h at 37 °C with DMSO, MC, staurosporine (Stauro) and Q-VD-Oph (QVD) 
respectively. After centrifugation, the pellet was lysed with SDS-b and evaluated for amount of 
PARP, phospho-ERK, phospho-MARCKS, ERK and beta-actin by SDS-PAGE and Western Blot. 
Data shown are representative for 3 independent experiments. 
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14.2 MC decreases phosphorylation of p38 MAPK, ERK and 
Akt but not JNK/SAPK in HL60 cells  
The long term effect of MC seen on ERK phosphorylation is caspase-dependent 
and obviously only proximal to caspase activation and apoptotic disassembly of 
the cell. In order to investigate if the short term effects of MC observed in PMNL 
could be seen in HL60 cells as well, HL60 cells were incubated with vehicle, MC 
or staurosporine and stimulated with fMLP and PMA as done with PMNL (Fig. 
30). 
Interestingly, the basal phosphorylation state of the observed kinases could not be 
further elevated by fMLP or PMA. This is probably due to the upregulation of Ras 
activity not only activating the ERK cascade but also cross signaling to other 
kinase pathways. Nonetheless, MC showed a strong decrease in phosphorylation 
of ERK and p38 MAPK, a slight decrease in Akt phosphorylation but no effect on 
JNK/SAPK. 
Phosphorylation of MARCKS was also unaffected by MC reflecting the results in 
PMNL and hinting that PKC is not involved. Staurosporine showed strong 
inhibition of MARCKS phosphorylation but not of ERK phosphorylation. This 
would indicate that in HL60 cells activation of ERK and PKC are mutually 
independent events. 
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Fig. 30 MC reduces phosphorylation of the MAP Kinases ERK, p38 MAPK as well as Akt/PKB 
in fMLP-stimulated HL60 cells. HL60 cells (5 × 107 /ml)  were incubated in PGC  for 30 min at 
37 °C with DMSO, MC or staurosporine (Stauro) before stimulation with 100 nM fMLP for 1.5 
min (A) or 100 nM PMA for 3 min (B). Incubation was stopped by adding SDS-b and putting the 
samples on ice. After cooking and sonification, samples were loaded to an SDS-PAGE gel and 
amounts of proteins were measured using specific antibodies. Data are representative for 2-5 
independent experiments. 
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14.3 MC reduces ERK phosphorylation in unstimulated 
cells 
Although fMLP and PMA did not lead to increased phosphorylation states of the 
tested kinases in HL60 cells, MC reduced especially ERK and p38 MAPK 
phosphorylation.  
As seen in Fig. 31, the decrease in ERK phosphorylation by MC can also be 
observed in unstimulated cells and is comparable to fMLP-treated HL60 cells. 
Independent of any external stimuli, MC can target and interrupt MAPK signaling 
which is upregulated in HL60 cells.  
 
 
Fig. 31 MC reduces phosphorylation of ERK in unstimulated HL60 cells. HL60 cells (5 × 107  
cells/ml) were incubated in PGC for 30 min at 37 °C with DMSO, myrtucommulone (MC) or 
staurosporine (Stauro) before stimulation with 100 nM fMLP for 1.5 min. Incubation was stopped 
by adding SDS-b and putting the samples on ice. After cooking and sonification, samples were 
loaded to an SDS-PAGE gel and amounts of proteins were measured using specific antibodies. 
Data are representative for 3 independent experiments. 
 
14.4 PTPase activity is not affected by MC in HL60 cells 
 
According to the results in PMNL on PTPase activity, we wanted to evaluate the 
effect of MC on PTPase activity in HL60 cells (Fig. 32). Instead of leading to an 
inhibition of PTPases as observed in PMNL, in HL60 cells, MC was not able to 
significantly affect PTPase activity (Fig. 32A). Interestingly, the effect of MC on 
the phosphorylation of tyrosine residues was also abolished (Fig. 32B). This 
indicates that the decrease in ERK phosphorylation after treatment with MC is 
seemingly not mediated by action on tyrosine kinases and phosphatases. 
fMLP - - + + + + 100 nM
P-ERK 1/2
β-actin
DMSO 0.2 - 0.2 - - - [%]
MC - 10 - 3 10 - [µM]
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Fig. 32 MC has no effect on PTPase activity in HL60 cells.  A) PTPase activity. Cells (8 × 105) 
were incubated for 30 min at 4 °C with DMSO, MC or PAO. After lysing the cells and 
centrifugation of the lysates, p-nitrophenyl phosphate (pNPP) was added to the supernatants and 
absorption at 405 nm was measured in a Victor™ plate reader. n = 3 ± S.E. **p<0.01 B) 
Phosphorylation of tyrosine residues. 5 × 106 cells were incubated for 30 min at 37 °C with 
DMSO, MC or staurosporine (Stauro). Incubation was stopped by adding SDS-b and putting the 
samples on ice. Data are representative for 3 independent experiments. 
 
14.5 MC fails to reduce the amount of GTP-bound Ras in 
HL60 cells 
ERK phosphorylation in HL60 cells is strongly reduced by MC. In PMNL this 
was at least partly due to inhibition of Ras activation and to a decrease in the 
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active GTP-bound form of Ras. We evaluated whether similar effects concerning 
Ras activation could be observed in HL60 cells. An effect on Ras activity by MC 
might be the reason for `normalised´ activity of signaling pathways and higher 
susceptibility to subsequent events (like apoptosis), since N-Ras is constitutively 
active in HL60 cells.  
Surprisingly, no effect of MC on amounts of Ras-GTP in fMLP- or PMA-
stimulated HL60 cells could be observed (Fig. 33). The kinase inhibitor 
staurosporine also failed to reduce the amounts of Ras-GTP, indicating high 
stability of the overactivated Ras-GTP complex in HL60 cells. 
 
 
Fig. 33 MC  fails to reduce the amount of GTP-Ras in PMA and fMLP-stimulated HL60 cells.  
HL60 cells (5 × 107/ml) were incubated for 30 min at 37 °C with DMSO, MC or staurosporine 
(Stauro) before stimulation with 100 nM fMLP for 1.5 min (A) or 100 nM PMA for 3 min (B). 
After stopping the reaction, cells were lysed and lysates were transferred onto Raf-Ras binding 
domain (Raf-RBD)-coupled Sepharose beads. 5 µl of lysates were directly assigned to SDS-PAGE 
and Western blot for detection of total amounts of Ras. Ras-GTP bound to the Sepharose beads 
was extracted from the lysates by centrifugation, followed by several washing steps and addition 
of SDS-b. Samples were then loaded to an SDS-PAGE gel and amounts of Ras-GTP were 
quantified by Western Blot using a Ras-specific antibody. Data are representative for 3 
independent experiments.  
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14.6 MC does not affect the Ras/Raf/MEK signaling cascade 
In HL60 cells, MC did not inhibit Ras activation although the phosphorylation of 
ERK was strongly reduced. To test wether MC might have an effect on the 
kinases downstream of Ras, we assessed the phosphorylation states of c-Raf and 
MEK 1/2 in HL60 cells after preincubation with MC and staurosporine and 
subsequent stimulation with fMLP and PMA (Fig. 34). 
 
 
Fig. 34 MC has no effect on phosphorylation of c-Raf and MEK 1/2 in HL60 cells. HL60 cells 
(5 × 107/ml) were incubated for 30 min at 37 °C with DMSO, MC or staurosporine (Stauro) before 
stimulation with 100 nM fMLPfor 1.5 min (A) or 100 nM PMA for 3 min (B). Samples were loaded 
to an SDS-PAGE gel and amounts of proteins were quantified by Western Blot using phospho-C-
Raf (Ser338) and phospho-MEK 1/2 specific antibodies. Data are representative for 3 independent 
experiments.  
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No effect of MC on phosphorylation of c-Raf or MEK 1/2 could be observed. 
Again, fMLP or PMA could not further increase the amount of phosphorylation of 
c-Raf and MEK 1/2 indicating the maximal activation state of the signaling 
pathway in HL60 cells. Staurosporine was not able to reduce the amounts of 
phospho-MEK 1/2 but apparently had a slight effect on c-Raf phosphorylation. 
According to the effect of staurosporine on MARCKS phosphorylation (Fig. 30), 
staurosporine obviously still has an effect on PKC in HL60 cells leading to 
decreased MARCKS and c-Raf phosphorylation. Nonetheless, this decrease is not 
sufficient to reduce MEK phosphorylation. 
The inhibition of ERK by MC in HL60 cells due to decreased phosphorylation is 
obviously not mediated by the Ras/Raf/MEK pathway. The influence of MC on 
ERK must therefore be caused by interference with another pathway upstream of 
ERK.  
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15 MC and apoptosis induction 
 
Previous studies aiming to evaluate the physiological and biochemical effects of 
MC on whole cells as well as on isolated enzymes and molecules mainly 
concentrated on effects of MC in inflammation and bacterial infections and on 
antioxidant properties of the substance. Only little is known about the effects of 
MC on apoptosis induction and on cancer cells [22]. The anticancer drugs which 
nowadays are in use partly show severe side effects like gastrointestinal and 
cardiac damage, bleeding, fever etc.. They always bear the risk of inducing 
chemoresistance in cancer cells. The development of new drugs and the 
improvement of common treatment against cancer are in progress and there is 
great need to find new substances with selective cytotoxicity for cancer cells and 
marginal or no damaging effects on non-degenerated cells. 
 
Indeed, MC could reduce cell viability in several cancer cell lines with EC50 
values between 3 and 9 µM, whereas non-transformed cells (PMNL, PBMC) were 
affected only at concentrations of > 20 µM and > 50 µM MC. Although plasma 
levels of MC after oral application of the substance are yet to be determined, 
hyperforin, a prenylated acylphloroglucinol with structural similarities to MC, 
was already tested in this respect. After three oral doses of 300 mg/kg of 
Hypericum perforatum extracts (correlating to 3 times 14.8 mg hyperforin) per 
day, plasma levels between 0.18 µM (steady state) and 0.28 µM (maximal 
concentration) hyperforin were reached in humans [203]. Assuming that MC 
shows similar bioavailability and gives comparable plasma concentrations, 
cytotoxicity for non-transformed cells should be evanescent, although the effects 
on cancer cells and on signal transduction pathways would perhaps not reach half 
maximal inhibition. Tests concerning bioavailability and different modes of 
administration of MC in rats to reach concentrations of optimal activity in cancer 
cells are recently conducted.  
 
Apoptosis is a mechanism often deregulated in cancer cells. Pathophysiological 
properties of cancer cells include increased cell growth, proliferation, changes in 
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metabolism (to meet higher energy needs of the cells), as well as increased 
invasiveness and metastasising properties. Changes in degenerated cells include 
upregulation of signal transduction pathways, increased metabolism and reduced 
apoptotic signaling. This includes effects on e.g. p53, NFκB and PKB/Akt which 
also leads to altered gene expression usually worsening the situation [204]. 
Apoptosis induction in cancer cells is therefore one of the most important 
strategies for cancer therapy. In the present investigation the apoptosis inducing 
properties of MC were elucidated, showing that MC induces apoptosis involving 
the intrinsic pathway. 
Since MC showed the strongest cytotoxic effects in leukaemic cells with EC50 
values of 3 - 4 µM, in this study the focus was placed on promyelocytes (HL60), 
pre-mature monocytic cells (MM6) and Jurkat cells. MC concentration-
dependently induced cleavage (and therefore activation) of caspases 2, 3, 7, 8 and 
9 in HL60 cells and MM6 cells, starting at concentrations of 3 to 10 µM. PARP, 
as main substrate of caspase 3, was also cleaved and inactivated suggesting 
apoptosis induction. Comparing the results to caspase cleavage in PBMC, it was 
obvious that tenfold higher concentrations of MC were needed to induce cleavage 
of PARP and caspase 3. Cycloheximide (CHX) is an inhibitor of protein 
biosynthesis by blocking translational elongation in eukaryotes. Furthermore, 
CHX exerts toxic effects leading to DNA damage. Its apoptosis inducing effects 
are probably due to decreased synthesis of short-lived death antagonists and to 
decreased glucose uptake [205]. CHX was used as positive control for 
cytotoxicity in HL60 and MM6 cells and showed PARP and caspase 8 cleavage as 
expected. 
Daunorubicin is an anthracycline commonly used as chemotherapeutic drug. It 
slows the growth of cancer cells by DNA intercalation, thus blocking 
transcription. Furthermore, it can stimulate the production of superoxide anions 
[206, 207]. Daunorubicine exerts cytotoxic effects especially for rapid growing 
cells but has also severe side effects due to cytotoxicity if not quickly 
administered intravenously. In PBMC, 1 µM daunorubicin induced cleavage of 
PARP, caspase 9 and 3, showing its cell death inducing potency also in non-
transformed PBMC.  
One could argue that this selective effect of MC on cancer cells, especially 
concerning numbers of viable cells, could be due to the simple difference in 
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proliferation rates of the cells. This could be refuted by stimulation of PBMC with 
5 µg/ml PHA-L for 24 hours, which significantly increased numbers of PBMC in 
the G2-phase (from 1.4 to 16% in PHA-L-stimulated cells, data not shown). MC-
induced cytotoxicity in PHA-L-stimulated cells was not significantly increased 
and EC50 values ranged around 20-30 µM (data not shown). 
Regarding the time-course of caspase 3 and 9 as well as PARP cleavage in HL60 
cells, MC-induced cleavage started after 9 hours preincubation of the cells. 
Staurosporine inhibits protein kinases by competitive binding of ATP binding 
sites [208, 209]. Although the exact mechanism of apoptosis induction by 
staurosporine is not totally understood, activation of caspase 2 might be involved. 
The staurosporine-induced caspase and PARP cleavage and apoptosis induction, 
as observed in Western Blot experiments as well as in DNA fragmentation assay 
and Annexin V/PI-assay (data not shown), started significantly earlier than the 
effects of MC after less than 3 hours preincubation with staurosporine. Such early 
apoptosis-inducing effects of staurosporine were observed before [209]. 
The release of proteins from mitochondria is a hallmark of early apoptosis. 
Endonucleases (EndoG and AIF) leading to DNA fragmentation, as well as 
cytochrome c, activating caspase 9, are released upon treatment with MC. DNA 
fragmentation could be detected in HL60 and MM6 cells by flow cytometry, after 
24 hours incubation with MC. Significant effects could be observed starting from 
10 µM MC in HL60 and MM6 cells whereas only 60 µM MC caused a  
significant effect in PBMC. Cytochrome c release was observed in HL60 cells and 
MM6 cells starting at 10 µM MC and in accordance with the time course of 
caspase and PARP cleavage (Fig. 5), the cytochrome c release started 6 to 9 hours 
after MC treatment. Furthermore, cytochrome c release by MC could not be 
inhibited by the pan caspase inhibitor QVD indicating that MC-induced 
cytochrome c release is caspase independent. This refutes the theory by our 
previous work where we assumed that caspase 8 activation precedes and even 
causes cytochrome c release by cleavage and activation of Bid to tBid [22]. 
Caspase 8 is probably rather activated in a feedback amplification loop by caspase 
9 and caspase 3 [86, 87].  
Concerning the preceding events that cause the release of cytochrome c and 
endonucleases from mitochondria, the effect of MC on the mitochondrial potential 
∆Ψm was evaluated. After 24 hours incubation, MC reduced ∆Ψm in MM6 cells 
 Discussion 115 
 
starting at 3 µM but not in PBMC. Interestingly, investigating ∆Ψm after 30 min 
incubation with MC, the loss of ∆Ψm induced by MC in PBMC was equal to the 
loss of ∆Ψm in MM6 cells (data not shown). Obviously, MC affects ∆Ψm in 
PBMC. Since endoxidation and ATPase activity are not downregulated in PBMC 
as compared to cancer cells [53], the reversible reaction of ATPase, hydrolysing 
ATP to ADP and phosphate, probably reconstitutes ∆Ψm (uncoupling induced 
ATPase activity). Thus, it can be concluded that the selectivity of MC for cancer 
cells starts at the level of mitochondria and probably involves alterations in 
mitochondrial metabolic enzyme activities. 
There is a strong debate regarding the order of membrane disrupting events (PTP, 
loss of ∆Ψm, mitochondrial swelling, MAC) in mitochondria which then 
subsequently lead to cytochrome c release and apoptosis induction.  
The MAC is formed upon oligomerisation of Bax (probably by involvement of 
tBid) and can be inhibited by the anti-apoptotic Bcl2. If the mechanism of 
mitochondrial apoptosis induction by MC involves opening of MAC, this should 
be inhibited by overexpression of Bcl2. However, MC still reduced cell viability, 
led to PARP and caspase 3 cleavage, induced loss of ∆Ψm and led to cytochrome c 
release in Bcl2-overexpressing Jurkat cells in the same manner as in MOCK-
transfected Jurkat cells. Thus, MAC formation is not required for apoptosis 
induction by MC. The second possibility of mitochondrial membrane disruption 
tested, was the formation of the PTP. By interacting with one of the PTPs 
numerous components, MC might be able to induce PTP opening. Chelerythrine 
and cyclosporine A were used as control reagents. Chelerythrine is able to directly 
target mitochondria and open PTP, whereas cyclosporine A is able to bind 
cyclophillin D and inhibits opening of the pore. The effect of MC on cell viability 
was not affected by CsA and by inhibiting PTP opening, whereas chelerythrine 
caused cytotoxic effects on both, MM6 cells and PBMC, which could be totally 
reversed by inhibition of PTP with CsA. Thus, also PTP formation is obviously 
not involved in MC-induced apoptosis. 
Is it possible that the intrinsic pathway of apoptosis induction is not the only mode 
of action involved in MC-induced apoptosis? Or does MC induce a caspase 
independent way of apoptosis? Both theories could be abandoned by testing MC 
in various Jurkat cell lines, deficient or defective in members of the extrinsic and 
intrinsic pathway. MC still reduced cell numbers and could induce PARP 
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cleavage regardless of deficiency in FADD, CD95 signaling or caspase 8 with 
comparable concentrations that are effective in wild type cells. Only in caspase 9-
deficient cells PARP cleavage and DNA fragmentation by MC was totally 
abolished. Also caspase 8 was not cleaved in caspase 9-deficient cells, indicating 
that caspase 8 activation observed in HL60 and MM6 cells is dependent on 
caspase 9 rather than constituting the event leading to cytochrome c release and 
caspase 9 activation. Surprisingly, the numbers of viable cells in caspase 9-
deficient cells are still reduced by MC. Untreated caspase 9-negative cells grew to 
a cell density of 0.49 × 106 cells/ml after 48 hours, whereas MC-treated cells only 
reached an amount slightly more than the starting concentration of 0.2 × 106 
cells/ml. What could be the reason for this persistent effect on caspase 9-deficient 
cells irrespective of the apoptosis induction by MC? 
Two possible reasons were checked. First, we tested if MC had necrosis-inducing 
effects and second, we analysed if the cell cycle was affected by MC. Neither 30 
µM MC nor 1 µM staurosporine could induce apoptosis or necrosis after 16 hour 
(or 24 hours, data not shown) incubation in caspase 9-deficient Jurkat cells, tested 
in the Annexin V / propidium iodide assay. The MC- and staurosporine-induced 
phosphatidylserine externalisation could be detected in caspase 9-deficient cells 
retransfected with caspase 9. Hence, necrosis is obviously not the reason for the 
decrease in cell numbers of caspase 9-deficient cells by MC. The results 
concerning staurosporine contradict results obtained by another group who could 
show that staurosporine induces apoptosis in a catalytically inactive caspase 9 
mutant cell line [209]. They stated that higher concentrations of staurosporine 
were needed in this mutant cell line than in normal cells to get similar apoptosis 
induction (60% apoptotic nuclei determined by DNA fragmentation assay after 24 
hours incubation with 5 µM staurosporine in JM319). The staurosporine 
concentration used (1 µM) as control in this study might have been not sufficient 
to see an effect in the Annexin V /propidium iodide assay.  
MC led to a slight inhibition of the cell cycle after 24 hours which caused 
increased numbers of cells in G2-phase in caspase 9-deficient and retransfected 
Jurkat cells. Staurosporine which is known to be a strong inducer of G2-phase 
arrest [210] shows a significant increase in cells located in G2-phase after 24 
hours for both cell types. This implies that although apoptosis induction by MC 
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depends on caspase 9, MC has another effect on the cell which leads to cell cycle 
arrest. 
 
 
Fig. Overview: Apoptosis induction by MC. (parts of lower importance are drawn translucent) In 
the present investigation, it could be shown that MC induces apoptosis in cancer cells by inducing 
the intrinsic way of apoptosis. Caspase 9 is essential whereas CD95, FADD and Caspase 8 are of 
no importance for apoptosis induction by MC. Loss of ∆Ψm and cytochrome c release induced by 
MC is independent of Bcl2 proteins and opening of the PTP. (further explanations see text) 
 
Many questions still remain and could not be answered during this thesis. Why do 
PBMC restore ∆Ψm and cancer cells do not? Is this the main difference for 
apoptosis induction by MC leading to selectivity of MC for cancer cells? What 
effect of MC in the cell leads to the loss of ∆Ψm and cytochrome c release? 
 
Common compounds used for treatment of cancer or applied in in vitro studies 
concerning apoptosis investigations, often induce apoptosis by the intrinsic 
pathway due to inhibition of protein biosynthesis (cycloheximide) and due to 
DNA-crosslinking, -intercalation and topoisomerase inhibition (cisplatinum, 
daunorubicin, etoposid). Apoptosis induction is then triggered, accompanied by 
cell cycle arrest and/or changed protein expression. The effect of MC seems to be 
more multifaceted. Apoptosis induction is not as rapid in onset as for the kinase 
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inhibitor staurosporine but takes more than 6 hours until effects on caspases and 
PARP cleavage can be seen. On the other hand, the loss of ∆Ψm induced by MC is 
a very rapid event occurring after 30 min without any selectivity for non-
transformed cells or cancer cells. Instead of selectively triggering the opening of 
MAC or PTP, the effect of MC on mitochondria seems to be rather unspecific.  
At a first glance, MC seems to be a quite hydrophilic and polar substance. The 
presence of two vinylog carboxylic acids and several hydroxy and carbonyl 
residues support this assumption. Some publications state however, that within the 
MC molecule strong hydrogen bonds are formed rendering the molecule more 
lipophilic [1, 19]. This raises the question, if the effect of MC might be an 
unspecific incorporation or adsorption in/onto membranes in general. MC may 
possibly adhere to plasma membranes or enter the cell and insert into 
mitochondrial membranes where it changes membrane properties and leads to 
membrane disruption. At least the non-prenylated acylphloroglucinol hyperforin 
has been shown to be able to modify neuronal membranes in vivo [211]. 
Hyperforin changed membrane fluidity as determined by fluorescence anisotropy 
of diphenylhexatriene. In order to evaluate the effect of hyperforin on 
synaptosomal uptake of norepinephrine, dopamine and serotonine it was observed 
that hyperforin does not bind to the respective transporters. It was rather 
postulated that hyperforin might either mechanically change the physical 
conformation of the lipid bilayer leading to a structural change in receptor and 
channel proteins or that hyperforin directly interacts with e.g. channel proteins 
leading to elevation of [Na+]i and thus inhibiting the Na+ gradient-dependent 
uptake of neurotransmitters.  
Recently, investigations are conducted showing an interaction of MC with 
membranes isolated from platelets that are protein free by digestion with 
proteinase K (unpublished data by A. LeBlanc). Nevertheless, the effects of MC 
on isolated proteins such as 5-LO, mPGES-1 and COX-1 [46] [18] must be 
explained somehow. 5-LO as well as mPGES-1 and COX-1 activities all depend 
on binding of fatty acids (FA) such as arachidonic acid and derivatives. Maybe 
MC is able to interfere with FA-binding domains of certain enzymes. Another 
publication about acylphloroglucinols isolated from the fern Dryopteris 
crassirhizoma showed that filixic-acid-ABP being structurally related to MC 
(already described in [11]) shows an inhibition of the fatty acid synthase with an 
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IC50 of 31.0 +/- 2.7 µM [212], an enzyme that synthesises palmitic acid from 
acetyl-CoA and malonyl-CoA. 
 
filixic acid-ABP 
This is of interest when taking into consideration that fatty acid synthase (FASN) 
inhibition can trigger apoptosis in MCF7, a human breast cancer cell line [213]. 
Zhou and colleagues could show that the FASN inhibitor C75 could induce 
apoptosis due to interference with phospholipid biosynthesis during S-phase. And 
indeed, filixic acids have been shown to possess tumor inhibitory activity [214]. 
Aside from its apoptosis inducing effects, MC obviously has another effect that is 
seemingly independent of caspase 9 and leads to an arrest of cell growth as seen 
in the experiments with caspase 9-deficient and retransfected Jurkat cells.  
As it will also be discussed later on in the section concerning the effect of MC on 
signal transduction, MC might induce changes in protein expression leading to 
reduced metabolic rates in the cell such as lipid biosynthesis which is needed for 
proliferation especially in cancer cells. 
 
When assessing the effect of MC on ROS production (data not shown), MM6 
cells were incubated with MC for 3 and 6 hours and a decrease in ROS production 
was observed. ROS can be produced during oxidative phosphorylation in 
mitochondria (which is visible as slight and steady increase of the baseline in 
untreated cells). The effect of MC on ROS production could not be reversed by 
the addition of cycloheximide (and therefore inhibition of proteinbiosynthesis) 
suggesting that altered gene expression induced by MC is not the reason for this 
effect. Furthermore, MC could reduce the oxidant properties of H2O2 added after 
3 or 6 hours incubation with MC (data not shown). 
MC might influence the oxidative phosphorylation leading to decreased formation 
of reactive oxygen species and additionally shows anti-oxidant properties. It must 
be mentioned that the experiments in the present study concerning ROS 
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production were conducted in unstimulated MM6 cells rather than in fMLP-
stimulated PMNL as performed by C. Feißt et al. [18]. Stimulation of 
granulocytes with fMLP leads to activation of the NADPH oxidase subunit p47 
phox by a PKC dependent mechanism which is responsible for oxidative burst and 
ROS production in granulocytes for fighting intruding pathogens. Also here MC 
showed a significant effect. 
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16 MC and signal transduction pathways 
 
16.1 Effects of MC on signal transduction in PMNL 
 
As implicated from the previous chapter, no convincing explanations could be 
found for the early effects that initialise apoptosis induction by MC. Although 
some hints exist that membranes, membrane associated receptors and their 
activation of signal transduction cascades leading to changes in protein expression 
and activity might be involved. 
 
The results of the loss of mitochondrial membrane potential after 30 min 
preincubation with MC showed that aside from the `late´ apoptotic events 
observed after hours of treatment, more rapid effects are induced by MC.  
C. Feißt et al. demonstrated a decrease in ROS production, decreased elastase 
release and a reduction of Ca2+ mobilisation from intracellular stores in fMLP-
stimulated PMNL which was caused by MC treatment for only 10 min. These 
effects were obvious in non-transformed granulocytes. Is there a connection of 
these effects to cancer and induction of apoptosis? Can any selectivity between 
non-transformed PMNL and HL60 cells which were tested alongside in this study 
be observed? 
 
Stimulation of granulocytes by chemoattractants such as LPS or fMLP is essential 
to evoke an acute inflammatory response and to destroy pathogens. Binding of 
these chemoattractants to the respective receptors initialises signal transduction 
events of high complexity which then elicit ROS production, degranulation, 
reassembly of the cytoskeleton and chemotaxis. Upon binding of fMLP to its 
receptor, the classical pathways involving G proteins, PLC, PKC and MAPK 
pathways are activated [158]. Upon fMLP stimulation and direct stimulation of 
PKC by the phorbolester PMA, we could indeed observe an increase of ERK 
phosphorylation in PMNL. Activation of these MAPK pathways plays an 
important role in inflammatory diseases and also in cancer. Additionally, many 
cancer cell lines exhibit constitutively overactivated MAPK cascades. Due to 
these reasons and due to the fact that MC affects Ca2+ signaling upon fMLP 
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stimulation [18], the influence of MC on signal transduction and especially 
activation of MAPK pathways was an interesting and promising approach.  
 
MC caused a strong inhibition of ERK phosphorylation in fMLP-stimulated 
PMNL, starting at a concentration of 3 µM. The p38 MAPK and JNK, as well as 
the kinase Akt/PKB were stimulated by fMLP and their activation could be 
inhibited by MC. Interestingly, staurosporine was not able to significantly inhibit 
phosphorylation of p38 MAPK, ERK and JNK. Only MARCKS and Akt/PKB 
phosphorylation was decreased by staurosporine. These results with MC indicate 
that the target for MC probably lies upstream of the mentioned kinase cascades. 
Staurosporine instead inhibits phospholipid and Ca2+-dependent kinases. This 
might explain the selective effect of staurosporine on PKC (MARCKS) and 
Akt/PKB in the present experimental setup.  
In view of our working hypothesis, the phosphorylation of MARCKS is an 
interesting point. MARCKS is a direct substrate of PKC which was thought to be 
involved in MAPK/ERK activation by fMLP [158], but obviously MC had no 
effect on its phosphorylation. This would mean that a) MC has no direct effect on 
PKC and b) MC has no effect on the upstream events leading to PKC activation 
after stimulation with fMLP. Both could be confirmed by stimulation of PKC with 
PMA and PMA + ionomycin (to exclude any effect of MC on Ca2+ concentrations 
causes an effect on PKC activity). Again, MC significantly reduced ERK 
phosphorylation but did not affect the amounts of phospho-MARCKS. This is 
quite astonishing since ROS-formation upon fMLP stimulation observed by Feißt 
et al. depends on activation involving PKC and was obviously inhibited by MC 
[18]. Hence, MC must clearly affect downstream events of PKC which then lead 
to decreased ROS-formation by NADPH oxidase or there are other possibilities 
aside from PKC to activate ROS. 
If MC does not affect upstream signaling of PKC then how is the PLC and IP3-
dependent release of Ca2+ from intracellular stores inhibited by MC? MC could 
possibly exert direct effects on release of IP3 from the plasma membrane or is able 
to affect membranes and membrane associated channels in Ca2+ storing 
organelles. 
It could be excluded that MC specifically inhibits the FPR receptor itself by 
testing MC in cells stimulated with other GPCR ligands. LTB4- , AA- and 5-
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HETE-increased ERK phosphorylation could also be inhibited by MC in similar 
manner as in fMLP-stimulated cells. AA is converted by 5-LO to 5-HpETE and 
further reduced to 5-HETE within the cell. 5-HETE then leads to ERK activation 
in a pertussis sensitive way [215]. This experiment should also prove that 
inhibition of AA-induced ERK activation by MC is not due to inhibition of the 5-
LO. BWA4C, a selective inhibitor for 5-LO, could prevent 5-LO-induced ERK 
activation but was not able to affect the activation of the pathway by 5-HETE. 
MC could inhibit both, AA- and 5-HETE-induced ERK phosphorylation, 
indicating that MC is obviously affecting 5-HETE signaling but not its synthesis. 
 
It was postulated that the activation of the MAPK pathway by fMLP functions via 
Gi proteins leading either to activation of phospholipases, PKC and activation of 
Ras, Raf or MEK by PKC or by direct interaction of the G protein with Ras [158]. 
Furthermore, a cross activation of tyrosine kinases by G proteins which then 
would lead to activation of Ras by Sos, the classical GEF of RTK signaling, 
appeared possible. The latter seemed an attractive target since it has been 
published that phosphorylation of tyrosine residues plays a considerable role on 
programmed cell death. Whether this apoptosis induction is due to inhibition of 
tyrosine kinases [216, 217], or due to activation [218, 219] is still discussed and 
also may depend on cell types and cell states. To check the possibility if MC was 
able to interfere with cross-activation from GPCRs to tyrosine kinases, protein 
tyrosine phosphatase activity was determined and the phosphorylation state of 
tyrosine residues was checked. Rather than increasing PTPase activity in PMNL, 
MC slightly reduced PTPase activity concentration- and time-dependently 
resulting in increased phosphorylation of tyrosine residues. In view of the time 
dependency of inhibition of ERK and MEK phosphorylation by MC in PMA-
stimulated cells, it is interesting that MC did not totally abolish phosphorylation 
but rather led to a delay in activation and an attenuation of 
activation/phosphorylation intensities. Again, phosphorylation of MARCKS was 
rather slightly increased by MC over the time period monitored. Hence, 
interaction of proteins downstream of PKC might be hindered but not totally 
inhibited by MC.  
The downstream events of fMLP stimulation leading to ERK phosphorylation are 
thought to involve Ras and Raf [158]. The next logical step was to evaluate if Ras 
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activity stimulated by fMLP and by PMA was affected by MC. MC led to a 
reduction of Ras-GTP in PMNL stimulated with either stimuli starting at 
concentrations as low as 0.3 and 1 µM. Note that phosphorylation of c-Raf on 
serine residue 338 was diminished by MC although not as strongly as the effect on 
Ras. Phosphorylation of the activatory site of B-Raf (Ser 445) was not affected by 
MC. Thus, it can be stated that the effect of MC on the MAPK cascade in PMA- 
and fMLP-stimulated PMNL must be at the level of Ras activation. Either MC 
hinders activation of Ras by the receptor or the respective upstream signaling 
events or MC possibly has a stimulating effect on the intrinsic GTPase activity of 
Ras.  
Phosphorylation of MEK1/2 is the subsequent event after Raf activation and was 
also inhibited by MC. Nevertheless, one interesting difference between fMLP- 
and PMA-stimulated PMNL was observed: phosphorylation of ERK 1/2, MEK 
1/2 and c-Raf in PMA-stimulated PMNL is not as strongly affected by MC as in 
fMLP-stimulated cells. Phosphorylation of ERK and MEK in fMLP-stimulated 
PMNL is totally abolished with 30 µM MC whereas in PMA-stimulated cells a 
residual phosphorylation remains, concordant with the phosphorylation state in 
fMLP-treated cells after treatment with only 3 µM MC. This implies the 
involvement of more than one possible pathway leading from PKC to MEK and 
ERK activation, whereas only one pathway is affected by MC (see Fig. Possible 
pathways affected by MC in PMA- and fMLP-stimulated PMNL).  
It was found before that indeed PKC activation is not necessary for Raf activation 
by fMLP [158] and that fMLP-induced ERK activation does not depend on PKCγ 
[220]. So PKC which was unaffected by MC is probably not involved in fMLP-
stimulated MAPK signaling. 
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 Fig. Pathways possibly affected by MC in PMA- and fMLP-stimulated PMNL. (parts of lower 
importance are drawn translucent) This figure tries to explain the differences of MC effects in 
PMA- or fMLP-treated cells. PMA activates PKC which in turn activates Ras, Raf or MEK. MC 
possibly inhibits initial activation or increases GTPase activity of Ras leading to decreased 
amounts of Ras-GTP. This way, signaling  to Raf is abolished. Activation of Raf and MEK by PKC 
is not inhibited by MC, thus explaining the residual phosphorylation of Raf, MEK and ERK as 
observed in the present study (further explanations see text). fMLP activates the FPR1 leading to 
Ras activation. Here MC cannot inhibit the nucleotide exchange in Ras, but probably increases the 
GTPase activity rendering Ras inactive. Since PKC signaling plays no or only a minor role in 
MAPK activation (see text), the inactivation of Ras by MC leads to a total decrease in Raf, MEK 
and ERK phosphorylation. 
 
16.2 Effects of MC on signal transduction in HL60 cells 
 
After elucidating the inhibitory effects on ERK phosphorylation by MC in PMNL 
the first question was if this could also be observed in HL60 cells, if these effects 
persisted over the time (16 hours) and if this led to decreased (inhibitory) 
phosphorylation of BAD, the proapoptotic Bcl2 protein. HL60 cells show massive 
overactivation of the Ras/Raf/MEK/ERK cascade due to a mutation of N-Ras 
which impairs the intrinsic GTPase activity of the small G protein [129, 221]. 
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This leads to strong activation and phosphorylation of downstream targets. One of 
these targets is the proapoptotic Bcl2 protein BAD which is bound to 14-3-3 
proteins and located in the cytosol when phosphorylated, being unable to induce 
apoptotic events on mitochondria [222]. If ERK phosphorylation is diminished by 
MC in HL60 cells also BAD phosphorylation should be reduced rendering the 
protein able to translocate to mitochondria and thus to induce apoptosis. It was 
clearly shown that Bcl2 overexpression did not prevent cytochrome c release, loss 
of ∆Ψm or apoptosis induction induced by MC excluding the participation of Bcl2 
proteins to the apoptosis inducing effect. Regarding the long-term effect in HL60 
cells, MC reduced ERK and MARCKS phosphorylation while inducing PARP 
cleavage and apoptosis. By inhibiting caspases with the pan caspase inhibitor 
QVD, this effect could be reversed. Long-term inhibition of ERK and MARCKS 
phosphorylation might therefore depend on caspase activity.  
 
In short-term experiments, similar to the ones conducted in PMNL, neither fMLP 
nor PMA stimulation of HL60 cells gave a significant additional activating effect 
on the kinases analysed. Phosphorylation states, especially of ERK and p38 
MAPK, were quite high. Nonetheless, MC showed a considerable decrease in 
phosphorylation of p38 MAPK, ERK and a slight decrease in PKB/Akt activation. 
JNK/SAPK and MARCKS were unaffected by the MC concentrations used. 
Interestingly, 2 µM staurosporine could inhibit phosphorylation of the PKC 
substrate MARCKS but did not show an effect on any other kinases.  
If fMLP and PMA stimulation showed no increase in signaling events, how does 
MC influence signaling cascades? Unstimulated HL60 cells were pretreated with 
MC and it was observed that independently of any stimuli MC could decrease 
ERK phosphorylation. To further elucidate if tyrosine kinases and phosphatases 
were influenced by MC the effects of MC on PTPases in HL60 was assessed. 
There was no significant effect of MC observed in HL60 cells in this respect. 
Obviously, the effect of MC in HL60 cells hinders MAPK signaling 
independently of any receptors. Has MC a direct target in the MAPK cascade? We 
tested whether Ras-Raf or Raf-MEK interactions are targeted by MC directly. 
Suprisingly neither Ras, nor c-Raf and MEK 1/2 are inhibited by the 
concentrations of MC tested in HL60 cells. From this we can conclude that the 
influence on Ras, c-Raf and MEK 1/2 seen in PMNL is not observed in HL60 
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cells and therefore is negligible for the inhibitory effect of MC on ERK 
phosphorylation. When PMNL are treated with the non-hydrolysable GTP 
analogue GMP-PNP, incubated with MC and stimulated with fMLP, MC is no 
longer able to decrease amounts of Ras-GTP (data not shown) in PMNL. By 
treatment with GMP-PNP, Ras in PMNL is no longer able to process GTP to GDP 
by GTPase activity. This mimics the mutational change found in HL60 where 
GTPase activity of Ras is impaired. The results for MC in these cells imply that 
MC does not inhibit loading of Ras with GTP (induced by fMLP) but rather 
stimulates GTPase activity of Ras in PMNL. This process is not applicable to 
HL60 cells due to the Ras mutation. Nonetheless, ERK phosphorylation in HL60 
is significantly reduced by MC although Ras seems unaffected. Even though Ras 
is affected in PMNL, this cannot be the sole reason for decreased ERK 
phosphorylation. To activate ERK, a complex consisting of Ras, Raf, MEK as 
well as the scaffolding proteins KSR and CNK is formed [171, 172]. Another 
possible mode of action of MC could be the prevention of transmitting the signal 
from the Ras/Raf/MEK complex towards ERK. 
 
Although the mechanism by which MC reduces ERK phosphorylation could not 
totally be elucidated, it is clear that: a) MC probably does not affect the FPR 
directly since in unstimulated HL60 cells there was still a significant decrease in 
phospho-ERK, b) all pathways upstream of PKC (Giβγ, PLC, DAG release) are 
unaffected since phospho-MARCKS is not reduced by MC in fMLP-stimulated 
cells, c) MC has an effect on fMLP-induced Ca2+ release from intracellular stores, 
possibly by interacting with IP3-receptors or by interacting with organelle 
membranes directly [18], d) since Ras, Raf and MEK 1/2 activity in HL60 cells is 
not influenced by MC, upstream events of this cascade (including MEKK1) are 
probably not involved in the inhibitory effect of MC on ERK, e) MC possibly 
inhibits transmission of the signal from the Ras/Raf/MEK complex  towards ERK 
or f) MC might target ERK directly (see Fig. Comparison of MC effects in PMNL 
and HL60 cells). 
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Fig. Comparison of MC effects in PMNL and HL60 cells. (parts of lower importance are drawn 
translucent) In PMNL, MC inhibited activation of Ras, Raf, MEK and ERK, independently of PKC 
or RTKs. Whereas in HL60, Ras, Raf and MEK seemed unaffected by MC although 
phosphorylation of ERK was abolished by MC as strongly as in PMNL. Here, MC probably 
inhibits signaling from the Ras/Raf/MEK complex towards ERK, inhibits ERK directly or affects 
an alternative pathway leading directly from the GPCR to ERK (further explanations see text). 
 
The activation of ERK can lead to manifold events within the cell. ERK alters 
gene expression by activation of transcription factors such as Elk-1, c-Myc and 
others [223] which lead to expression of growth factors [224, 225], anti-apoptotic 
proteins (e.g. Bcl-Xl) [226], proteins influencing cell cycle progression [227] and 
inhibition of the expression of pro-apoptotic genes [227, 228]. Furthermore, it was 
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shown that LPS-induced chemotaxis in neutrophils is regulated by the coordinated 
action of p38 MAPK and ERK 1/2 [229]. And indeed, it was found that MC could 
inhibit chemotaxis in PMNL induced by fMLP (unpublished data, A. Henkel, 
Tübingen).  
ERK, aside from other signaling pathways (such as SAPK/JNK or PKB/Akt), can 
activate NFκB involving IκB kinase and IκB [230]. MC reduced phosphorylation 
of NFκB concentration-dependently in IL-1β- and TNFα-stimulated PBMC as 
well as in unstimulated cells (data not shown). Additionally, the transriptional 
activity of NFκB, as assayed by luciferase assay in chronic myeloid leukemia 
K562, was inhibited by MC with an IC50 of 3.0 ± 0.3 µM (unpublished data, 
M.Schumacher, Luxembourg).  
 
17 Conclusion 
 
Stimulation of neutrophils with chemoattractants such as fMLP is critical to 
establishing an acute inflammatory response mediated by upregulation of 
signaling pathways leading to activation of e.g. ERK and NFκB. ERK was shown 
to directly phosphorylate and activate key enzymes of eicosanoid biosynthesis as 
for example 5-LO [231] or cPLA2 [232] and thus stimulating production of further 
mediators of inflammation such as leukotrienes and prostaglandins. But also gene 
expression is upregulated by activation of these signaling pathways. NFκB is an 
important transcription factor e.g. for expression of genes for COX-2 and IL-6. By 
inhibiting signaling cascades, the events leading to innate immune response and 
the expression and release of further immune stimulative substances such as 
interleukins can be effectively inhibited. In many diseases the signals from 
chemoattractants leading to neutrophil responses are of considerable importance 
and inhibition of the signaling pathways has a beneficial effect.  Our present data 
support that MC exerts potent anti-inflammatory properties by inhibiting 
activation of neutrophil signal transduction pathways.  
 
Furthermore these pathways are also closely connected with the development of 
cancer. HL60 cells display cancerogenous properties by overactivation of the 
Ras/Raf/MEK/ERK cascade and elevated gene expression mediated by c-Myc, 
leading to increased cell proliferation. Overactivation of NFκB by stimulation of 
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macrophages or T-lymphocytes with IL, endotoxins like LPS and TNFα not only 
triggers inflammatory responses (IL-1, -6, -8 and TNFα release), leading to a 
positive stimulation feedback loop towards NFκB, but also, if downregulation of 
the NFκB activity fails, chronic inflammation and cancer can be the outcome 
[233]. By inhibiting signaling pathways that might initially lead to chronic 
inflammation and then, by inducing cellular and DNA damage, might promote 
cancer, MC might be a potential preventive drug for cancer. 
 
Not only preventive effects of MC on cancer development can be reasoned.  As 
could be shown in the present investigation, MC effectively and selectively 
induces apoptosis in cancer cells. It can be speculated that changes in gene 
expression due to the inhibition of signal pathways in cancer cells might lead to 
induction of apoptosis by MC. 
Taken together, MC proves to have the properties to be an effective treatment for 
inflammation and cancer and although many questions about its exact mode of 
action still have to be resolved, it will be interesting to follow results concerning 
MC effects in vivo in animal and clinical trials. 
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18 Summary 
 
Extracts of the mediterranean plant myrtle (myrtus communis) have a long 
tradition in folk medicine as a remedy for the treatment of infections and 
inflammatory diseases. Over the past decade, many scientific publications could 
support and rationalise the therapeutic use of myrtle preparations. In search for 
single components responsible for the beneficial effects, myrtucommulone A 
(MC), a non-prenylated acylphloroglucinol, was isolated from myrtle leaves and 
was shown to have strong anti-inflammatory properties. Anti-inflammatory drugs 
often show beneficial effects on development or progression of cancer. Therefore, 
it was reasonable to test whether MC might induce apoptosis and to evaluate its 
potential for treatment of cancer and especially leukaemia. 
 
18.1 MC induces apoptosis in cancer cells 
 
In the course of this study it could be shown that MC proved effective in inducing 
apoptosis in several leukaemia cell lines with marginal cytotoxicity for non-
degenerated blood cells. Aside from caspase cleavage, PARP cleavage and DNA 
fragmentation, loss of the mitochondrial membrane potential (∆Ψm) and 
cytochrome c release were the main features in MC-induced apoptosis.  
Furthermore, it was observed that caspase 9 and the intrinsic way was essential for 
apoptosis induction by MC, whereas caspase 8 and other components of the 
extrinsic pathway could be excluded as relevant mediators. The cause for 
cytochrome c release and activation of caspase 9 was independent of Bcl2 
proteins and of the opening of the mitochondrial apoptosis inducing channel or of 
the opening of the permeability transition pore. Aside from its apoptosis-inducing 
effect, MC reduced the numbers of viable cells in caspase 9-deficient Jurkat cells, 
although apoptosis was clearly abrogated. This effect was not related to necrosis 
but rather due to G2 phase arrest induced by MC. We conclude that MC may 
affect cell metabolism and signaling pathways, slowing growth of cancer cells 
compared to non-degenerated cells due to differences in activation of metabolic 
pathways and gene expression. 
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18.2 MC inhibits signaling pathways 
 
To elucidate the effects of MC on signal transduction pathways in PMNL and to 
check if similar effects are obvious in cancer cells, the phosphorylation states of 
several kinases in PMNL and HL60 cells were assessed. MC concentration 
dependently inhibited phosphorylation of ERK, p38 MAPK and Akt/PKB in 
leukaemic HL60 promyelocytes and in non-degenerated human PMNL. Whereas 
MC reduced activation of Ras, Raf and MEK upstream of ERK in PMNL, this 
pathway was unaffected by MC in HL60 cells. The effects of MC were also 
independent of PKC, since phosphorylation of the direct PKC substrate MARCKS 
was not affected. Although in PMNL MC blocked kinase activation following 
simulation with fMLP, PMA and other stimuli, in HL60 cells no stimulation was 
needed to see a strong inhibitory effect by MC on ERK phosphorylation. This 
influence of MC on especially ERK and p38 MAPK implies consequences on 
NFκB transcriptional activity in K562 chronic myeloid leukaemia cells and on 
fMLP-induced chemotaxis in PMNL.  
In conclusion, MC exhibits potent and manifold effects on signaling pathways 
involved in inflammation and apoptosis induction. Thus, MC has the potential as 
an effective and selective therapeutic to treat inflammation 
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